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ABSTRACT 
SUZANNE KURTZER MINTON: Stimulating Gq GPCRs in GFAP-positive glia blocks 
acute pain and itch 
(Under the direction of Ken D. McCarthy) 
 
Glial G protein-coupled receptor (GPCR) pathways have been linked to synaptic 
modulation. However, their roles in pain and itch processing are unknown and have been 
difficult to study because glia and neurons often express overlapping GPCRs. The transgenic 
mouse model glial fibrillary acidic protein-Designer Receptor Exclusively Activated by a 
Designer Drug (GFAP-DREADD) is a useful model for selectively stimulating Gq-GPCR 
pathways on GFAP-positive cells. Gq-DREADD is expressed in astrocytes, but not neurons, 
in the spinal cord. Imaging studies demonstrated that Gq-DREADD stimulation causes 
calcium increases in astrocytes in lamina II and V of the spinal cord in slices from Gq-
DREADD mice but not in those from wild-type mice. Stimulating Gq-DREADD caused a 
long-lasting antinociceptive phenotype for Gq-DREADD mice but not for wild-type mice as 
measured using the Hargreaves test. Selective stimulation of spinal cord and DRG Gq-
DREADD was sufficient to mediate this effect. Surprisingly, removal of the IP3R2 receptor 
did not affect Gq-DREADD-mediated antinociception, suggesting that stimulation of GFAP-
positive Gq-GPCR pathways can inhibit pain transmission in an IP3R2-independent manner. 
C-fos has been used as a marker of neuronal activity in response to noxious stimuli. Gq-
DREADD stimulation did not alter the ability of noxious stimuli to induce c-fos in the dorsal 
horn. Nociceptors make their central projections in the dorsal horn, and a decrease in 
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excitatory neurotransmission at this synapse would be antinociceptive. We examined this 
hypothesis by performing dorsal root stimulation experiments and found that Gq-DREADD 
stimulation did not modulate evoked field potentials in lamina II. The neurocircuitry that is 
used in pain processing has a large degree of overlap with itch-sensitive neurocircuitry. Gq-
DREADD stimulation was also shown to block histamine-dependent itch, and this phenotype 
appears to be peripherally mediated. Collectively, our experiments indicate that Gq-GPCR 
pathways in GFAP-positive glia can be antinociceptive in the setting of acute pain and can 
mediate antinociception in an IP3R2-independent manner. In addition, Gq-GPCR pathways in 
astrocytes can block acute itch. These data provide insight into the roles that glial Gq-GPCR 
pathways play in the modulation of acute pain and itch, which may lead to the development 
of novel therapies for chronic pain and itch neuropathies. 
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CHAPTER 1.  
THE ROLE OF ASTROCYTES IN NEUROPHYSIOLOGY 
1.1. A BRIEF HISTORY OF ASTROCYTE BIOLOGY 
Our understanding of astrocytes and their role in neurophysiology has expanded 
tremendously over the last 175 years. Prior to the mid-19th century, conventional wisdom 
stated that the central nervous system contained no connective tissue. But when the 
pathologist Virchow detected inflammation in the brain— an early observation of what 
would later be called “reactive astrogliosis” — he recognized that this could not be accounted 
for by neurons alone (Schmidt and Weber, 2006). In 1856 he coined the term “neuroglia,” 
writing that “this connective substance forms in the brain, in the spinal cord, and in the 
higher sensory nerves a sort of putty (neuroglia) in which the nervous elements are 
embedded” (Somjen, 1988). Astrocytes are a type of neuroglia, a category that also includes 
oligodendrocytes, NG2 glia, and microglia. 
Astrocytes comprise nearly half the cells in the brain (Ullian et al., 2001), and they are 
more than “putty.” Golgi started the modern study of glia by establishing that one may 
reliably distinguish glia from neurons by the lack of an axon. He also proposed that 
astrocytes provide nutritive support to neurons. Astrocytes are so named because their 
numerous fine bushy processes, which are distinct from the morphology of neurons or other 
glial cells, reminded early researchers of stars. In the early 20th century, Lugaro proposed 
that astrocyte processes contact both synapses and the vasculature (Somjen, 1988). The 
unique morphology of astrocytes plays a crucial role in their ability to perform many of their 
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functions in the central nervous system. This dissertation will further our understanding of 
the role and function of astrocytes. 
1.2. ASTROCYTE MORPHOLOGY 
1.2.1. Astrocytes ensheath synapses. 
An astrocyte possesses a small soma and several thick processes from which arise 
numerous fine processes. Unlike neurons, astrocytes do not have axons or dendrites, nor do 
they generate action potentials. Astrocytes can be divided into two major categories: grey 
matter astrocytes (protoplasmic astrocytes) and white matter astrocytes (fibrous astrocytes) 
(Miller and Raff, 1984). 
The classic astrocyte marker, GFAP, is a component of their thick processes; staining 
for GFAP highlights the classic “star-like” appearance of astrocytes (Bignami et al., 1972). 
However, GFAP immunostaining does not fully label the vast network of fine astrocyte 
processes. Astrocyte fine processes envelop both the pre-synaptic and post-synaptic elements 
of the synapse— a concept known as the tripartite synapse (Araque et al., 1999; Peters et al., 
1976). A single astrocyte can envelope 100,000 synapses (Bushong et al., 2002). As such, 
these cells are well-positioned to modulate synaptic transmission. 
Astrocyte processes show spontaneous motility at synaptic regions (Hirrlinger et al., 
2004) as well as activity-dependent changes in synaptic ensheathment (Cornell-Bell et al., 
1990a). The extent to which astrocytes ensheath synapses varies by region within the CNS. 
For example, astrocyte processes ensheath 57% of CA1 hippocampal synapses (Ventura and 
Harris, 1999). By contrast, only 29% of neocortical synapses have astrocyte ensheathment 
(Spacek, 1985). Haydon and coworkers have proposed a “synaptic island” model wherein a 
single astrocyte can coordinate the activity of groups of neurons through its contacts with 
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neighboring neuronal soma and dendrites (Halassa et al., 2007). In addition to making 
contacts with synapses, astrocytes also help compose and maintain the blood-brain barrier 
(BBB), which separates the circulatory system from the CNS. 
1.2.2. Astrocytes contact the cerebral vasculature. 
The German microbiologist and pharmacologist Paul Ehrlich discovered the BBB more 
than a century ago. He observed that when animals were injected with aniline dyes, staining 
would occur in all organs except for the brain. The BBB is composed of endothelial cells, 
which line the cerebral vasculature. The function of the BBB is to regulate ion gradients, 
facilitate nutrient transport, and shield the brain from potentially harmful substances 
(Hawkins and Davis, 2005). Endothelial cell permeability is restricted by the presence of 
high-resistance tight junctions (TJ) (Reese and Karnovsky, 1967). Astrocyte endfeet 
envelope CNS capillaries that compose the BBB (Risau and Wolburg, 1990; Davson and 
Oldendorf, 1967). 
During development, astrocytes provide factors important to the induction of the BBB 
(Janzer and Raff, 1987). Stewart and Wiley showed that avascular brain tissue transplanted 
into the coelomic cavity developed vasculature with BBB characteristics whereas avascular 
somite grafts transplanted into the cerebral ventricles developed leaky vasculature (Stewart 
and Wiley, 1981). This suggested that neural tissue provides some factor that is crucial for 
BBB development, but it was still unclear which neural tissue cells provided the crucial 
factor. Further evidence that astrocytes help induce the BBB came from Janzer and Raff who 
showed that injecting astrocytes into the anterior chamber of rat eyes formed aggregates 
containing non-leaky vasculature (Janzer and Raff, 1987). Astrocytes release several factors 
to induce the BBB including SSeCKS (Lee et al., 2003), TGF-β (Tran et al., 1999), and 
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GDNF (Igarashi et al., 1999). Astrocytes are involved in functional hyperemia: the 
coordination of blood flow to meet neuronal metabolic demands. Astrocytes are well 
positioned to regulate functional hyperemia by virtue of their extensive contact with the BBB 
and with synapses. 
1.2.3. Astrocytes couple to form cellular networks. 
While neurons often have extensive overlap in their dendritic arbors, astrocytes occupy 
largely separate anatomical domains (Bushong et al., 2002). Astrocytes exchange 
information via an extensive network of gap junctions: specialized intercellular connections 
that directly connect the cytoplasm of two cells (Giaume and McCarthy, 1996). Dye-coupling 
experiments illustrate the extent of astrocyte gap junction coupling. When an individual 
astrocyte in a brain slice is loaded with a low-weight fluorescent dye, dye diffusion through 
gap junctions labels tens to hundreds of neighboring astrocytes (Duffy and MacVicar, 1995; 
Gutnick et al., 1981). 
A gap junction is a cellular channel composed of two facing hemichannels, each of 
which contains a ring of six connexin (Cx) protein subunits (Caspar et al., 1977). Cx43 and 
Cx30, the major connexins in astrocytes (Dermietzel et al., 1991; Kunzelmann et al., 1999), 
are enriched at astrocytic perivascular endfeet (Simard et al., 2003). Gap junctions are 
permeable to ions and small (<1000 Da) signaling molecules such as ATP, inositol 1,4,5-
trisphosphate (IP3), calcium, glutamate, glucose, and lactate (Lawrence et al., 1978). 
Astrocyte gap junctions have also been implicated in pathological conditions such as mirror 
image pain, which is the spread of pain to the contralateral side from the neuropathic lesion 
(Milligan et al., 2003). Carbenoxolone, a gap junction decoupler, blocks neuropathy-induced 
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mirror image pain; this suggests that astrocytes mediate the spread of mirror image pain via 
gap junctions and are involved in pain processes (Spataro et al., 2004). 
1.3. ASTROCYTE FUNCTIONS 
1.3.1. Astrocytes support neurons metabolically.  
One of their earliest proposed functions for astrocytes was supplying nutrients to 
neurons. Although the brain composes only 2% of the body by weight, it consumes 20% of 
the body’s metabolic energy (Rolfe and Brown, 1997). Glucose is the major energy source 
for neurons in the central nervous system. Astrocytes provide metabolic support to neurons in 
an activity-dependent manner (Pellerin and Magistretti, 1994). During neuronal activity, 
astrocytes take up glucose from circulation (Kacem et al., 1998) and metabolize it to lactate 
or glycogen, which is then trafficked through astrocyte networks via gap junctions in order to 
sustain synaptic transmission and neuronal survival (Rouach et al., 2008; Pentreath and Kai-
Kai, 1982; Tsacopoulos and Magistretti, 1996). 
In addition to regulating glycogen, glucose, and lactate, astrocytes also regulate 
glutamate, which is the major excitatory neurotransmitter (Nicholls and Attwell, 1990). 
Excessive extracellular glutamate leads to excitotoxicity; astrocytes prevent excitotoxicty by 
controlling the concentration of extracellular glutamate (Brew and Attwell, 1987). In the 
glutamate-glutamine cycle, astrocytes take up extracellular glutamate via the glutamate 
transporter-1 (GLT-1), metabolize it to glutamine by glutamine synthetase, and then release 
glutamine to neurons as a precursor for glutamate synthesis (Schousboe et al., 1997). 
Meanwhile, GABA (γ-aminobutyric acid) is the main inhibitory neurotransmitter (Krnjevic 
and Schwartz, 1967). Since GABA is synthesized from glutamate, the glutamate-glutamine 
cycle in astrocytes is also important for supporting inhibitory neurotransmission (Kaufman et 
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al., 1986). In addition to supporting the metabolic activity of neurons, astrocytes are crucial 
in regulating the ionic and neurotransmitter content of the extracellular space. 
1.3.2. Astrocyte buffering of potassium and neurotransmitters. 
Astrocytes help maintain homeostasis by regulating potassium, glutamate, and GABA. 
Neurons release potassium into the extracellular space during normal neurotransmission. 
Excessive extracellular potassium leads to neuronal depolarization, hyperexcitability, and 
seizures (Wang and Bordey, 2008). Astrocytes import potassium released into the 
extracellular space during normal neuronal activity (Kuffler and Nicholls, 1966) and 
redistribute potassium through the astrocyte syncytium via gap junctions (Orkand et al., 
1966). Due to their extensive contacts with the cerebral vasculature, astrocytes can also 
release excess potassium into the blood stream (Newman, 1986). 
Potassium buffering by astrocytes is achieved using passive inward rectifying potassium 
(Kir) channels as well as electrogenic sodium-potassium ATPases (Ballanyi et al., 1987). In 
inwardly rectifying potassium channels, the inward flow of potassium ions is greater than the 
outward flow (Nichols and Lopatin, 1997). Kir4.1 is a glial-specific inwardly rectifying 
potassium channel (Takumi et al., 1995). The importance of astrocyte potassium buffering is 
illustrated by the conditional knockout of Kir4.1 in GFAP-positive glia, which results in 
severe ataxia, seizures, and early death (Djukic et al., 2007). 
In addition to potassium buffering, astrocytes regulate extracellular levels of glutamate 
and GABA. Glutamate, GABA, and other neurotransmitters are released with potassium 
during neurotransmission; astrocytes express transporters that take up neurotransmitters 
during synaptic activity (Huang et al., 2004; Shigetomi et al., 2011). Glutamate transporters 
work by importing glutamate with sodium while extruding potassium (Storck et al., 1992). 
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Astrocytes express the glutamate transporters GLT-1 and GLAST (Glutamate Aspartate 
Transporter) (Storck et al., 1992; Pines et al., 1992). GLT-1 and GLAST are differentially 
expressed in the CNS. GLT-1 is primarily restricted to astrocytes in adults. By contrast, 
GLAST is expressed by radial glia and astrocytes during early development but is 
downregulated in adults (Regan et al., 2007). 
Astrocytes regulate GABA concentrations via GABA transporters (GATs); they have 
been shown to express GAT-1 and GAT-3 (Brecha and Weigmann, 1994; Yan and Ribak, 
1998). GAT-3 in astrocytes regulates inhibitory synapses by controlling extrasynaptic GABA 
concentrations (Shigetomi et al., 2011). In conclusion, astrocytes are essential to maintaining 
CNS homeostasis by buffering substances released by neurons. 
1.4. ASTROCYTES REGULATE SYNAPSE FORMATION AND ELIMINATION. 
Sherrington proposed the concept of the “synapse”- a structure that allows a neuron to 
pass an electrical or chemical signal to another cell. The ability to form synapses was thought 
to be intrinsic to neurons (Ullian et al., 2004). Evidence that neurons alone were not 
sufficient to mediate synaptogenesis first came from the observation of a week-long delay 
between axons reaching their target and synapse formation, indicating that some other cell 
type had to be involved in synaptogenesis (Lund and Lund, 1972). 
Astrocytes are involved in inducing and stabilizing CNS synapses (Ullian et al., 2001). 
While neurons cultured alone form very few synapses, the addition of a feeder layer of 
astrocytes or astrocyte-conditioned media (ACM) to the neuronal culture leads to high levels 
of functional synapses (Pfrieger and Barres, 1997). ACM’s ability to promote synaptogenesis 
suggests that an astrocyte-secreted factor is involved. Indeed, later work showed that 
astrocytes secrete thrombospondins and cholesterol to promote synapse formation 
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(Christopherson et al., 2005; Mauch et al., 2001). Thrombospondins mediate synaptogenesis 
by binding neuronal α2δ-1 receptors (Eroglu et al., 2009). Synapse elimination is also crucial 
during development (Katz and Shatz, 1996); astrocytes trigger complement-mediated 
synapse elimination by releasing an unidentified molecular signal (Stevens et al., 2007). 
1.4.1. CNS injury causes gliosis. 
Astrocytes perform all of the above functions as part of normal physiology. During 
injury, astrocytes undergo reactive gliosis (or astrogliosis). Reactive astrocytes undergo 
hypertrophy, proliferate, and upregulate markers such as GFAP (Maxwell and Kruger, 1965; 
Latov et al., 1979). 
Reactive astrocytes are compromised in their ability to perform many of their normal 
physiological functions. For instance, glutamine synthetase expression is downregulated in 
reactive astrocytes in patients suffering from temporal lobe epilepsy (Eid et al., 2004). In vivo 
microdialysis studies have shown that extracellular glutamate levels rise to neurotoxic 
concentrations just before a seizure and remain elevated for at least fifteen minutes after 
seizure cessation (During and Spencer, 1993). Decreased glutamine synthetase disrupts the 
glutamate-glutamine cycle causing elevated extracellular glutamate; this can lead to seizures. 
Electrophysiological studies show that inducing gliosis in vitro causes astrocytes to 
switch their potassium channel expression from inwardly rectifying to outwardly rectifying 
(MacFarlane and Sontheimer, 1997). Kir channels are key to astrocyte potassium buffering 
(Ransom and Sontheimer, 1995). Gliosis results in decreased Kir expression, which could 
explain why gliotic tissue in an experimental model of epilepsy had impaired potassium 
buffering (Lewis et al., 1977). 
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Astrogliosis occurs in a wide range of neuropathological conditions including epilepsy 
(Wetherington et al., 2008), Alzheimer’s disease (Dickson et al., 1988; Schechter et al., 
1981), and chronic pain (Garrison et al., 1991; Tanga et al., 2004). It is controversial whether 
astrogliosis is detrimental or beneficial. Preventing gliosis with glial metabolic inhibitors 
blocks chronic pain (Meller et al., 1994). This suggests that astrogliosis is detrimental. By 
contrast, ablation of reactive astrocytes in a mouse model of traumatic brain injury 
exacerbated neural injury suggesting a beneficial role for gliosis (Myer et al., 2006). The 
observation that astrogliosis occurs in so many different kinds of neurological disorders 
suggests that glia may prove to be valuable therapeutic targets. The development of 
therapeutics that target glia will require a better understanding of glial cell signaling. 
1.5. ASTROCYTE GPCRS RESPOND TO AND MODULATE NEURONAL ACTIVITY. 
1.5.1. Review of heterotrimeric guanine nucleotide-binding protein (G-protein) coupled 
receptor (GPCR) pathways. 
GPCRs comprise a superfamily of receptors that bind ligands to activate intracellular 
signaling cascades (Stoddard et al., 1992). GPCRs are activated by a variety of ligands 
including hormones, neurotransmitters, odorants, and even photons (Kristiansen, 2004). The 
importance of GPCRs is reflected by the fact that roughly 30% of all pharmaceuticals work 
by modulating GPCRs (Hopkins and Groom, 2002). 
The human genome contains an estimated 900 GPCRs (Besnard et al., 2012). They 
regulate a wide range of physiological processes including metabolism, neurotransmission, 
growth, and visual perception (Wong, 2003). While the primary amino acid sequence of 
GPCRs varies widely, all GPCRs share certain structural features. Solving the crystal 
structure for rhodopsin confirmed that GPCRs are composed of seven-transmembrane α-
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helices separated by three intracellular and three extracellular loops; the helices are oriented 
with an extracellular N-terminus and an intracellular C-terminus (Palczewski et al., 2000).  
GPCRs undergo cycles of activation and inactivation (Iiri et al., 1998). In the inactive state, 
the heterotrimeric G-protein is composed of tightly associated GDP (guanosine-5’-
diphosphate)-bound Gα and Gβγ subunits. Upon ligand binding, GPCRs undergo a 
conformational change, catalyzing Gα to exchange GDP for GTP (guanosine-5’-
triphosphate) (Rhee, 2001). Then, GTP-bound Gα and Gβγ dissociate from the GPCR and 
activate downstream signaling effectors. Hydrolysis of Gα-GTP to Gα-GDP causes the 
reassociation of the heterotrimeric G-protein with the GPCR. 
Heterotrimeric G proteins signal through four classes of Gα proteins: Gs/olf, Gi/o, G12/13, 
and Gq (Cabrera-Vera et al., 2003). Gs/olf stimulates adenylyl cyclase (AC) whereas Gi/o 
inhibits it (Taussig and Zimmermann, 1998). G12/13 activates RhoGEFs (Ras homology 
guanine nucleotide exchange factors) (Hart et al., 1998). The Gq subfamily contains four 
types of α-subunits (Gαq, Gα11, Gα14, and Gα16) (Simon et al., 1991); they all stimulate 
phospholipase C β (PLC-β) (Knall and Johnson, 1998); Gαq/11 has also been shown to 
activate p63RhoGEF (Rojas et al., 2007; Lutz et al., 2005). While early work focused on Gα 
signaling, Gβγ also activates signal transduction cascades (Clapham and Neer, 1997). 
In the late 1950s, Sutherland and Rall were the first to characterize how GPCRs activate 
second messenger cascades. They showed that stimulation of various tissues with 
epinephrine or glucagon (both GPCR agonists) promoted the production of cyclic adenosine 
monophosphate (cAMP) by AC (SUTHERLAND et al., 1962; RALL and SUTHERLAND, 
 11 
1958; SUTHERLAND and RALL, 1958). Mammals express at least nine different isoforms 
of AC that vary in their pattern of tissue expression and regulation (Simonds, 1999). 
The production of cAMP by AC can be inhibited as well as stimulated. Gi-coupled 
GPCRs inhibit AC (Rodbell, 1995; Hildebrandt et al., 1983). Pertussis toxin catalyzes the 
ADP-ribosylation of Gi, which prevents GPCR coupling and inhibition of AC (Gilman, 
1995). 
Heterotrimeric G proteins and monomeric Ras GTPases both share the feature of being 
inactive in the GDP-bound state and active in the GTP-bound state (Vetter and Wittinghofer, 
2001). Guanine nucleotide exchange factors (GEFs) catalyze the exchange of GDP for GTP 
to generate the active Ras GTPase (Schmidt and Hall, 2002). Ras GTPase signaling is 
terminated via GTPase activating proteins (GAPs), which accelerate the intrinsic GTPase 
activity of Ras family members. 
The Ras-related small GTPase protein super family contains the Rho GTPase sub 
family (Jaffe and Hall, 2005). The human Rho GTPase sub family contains 22 members; the 
most extensively characterized members of this family are RhoA, Rac1, and CDC42 due to 
their ability to cause striking changes in cell morphology upon activation (Rojas et al., 2007). 
RhoGTPases have been implicated in a variety of cellular responses including gene 
transcription, embryogenesis, and actin cytoskeletal dynamics (Hall, 1998). 
Stimulation of G12/13-coupled GPCRs leads to Gα-GTP binding of the RH domain of 
RhoGEF (Kozasa et al., 2011). This induces a conformational change in RhoGEF, activating 
it (Hart et al., 1998). Activated RhoGEF can then activate the RhoGTPase by promoting the 
release of bound GDP, which then allows the subsequent binding of GTP (Schmidt and Hall, 
2002). 
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Most GPCRs that couple to G12/13 also couple to Gq (Kozasa et al., 2011). Gq-coupled 
GPCRs stimulate PLC-β, which catalyzes the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) to IP3 and diacylglycerol (DAG) (Smrcka et al., 1991; Taylor et al., 
1991). IP3 binds IP3 receptors on the endoplasmic reticulum (ER) and induces calcium 
release (Streb et al., 1983). PLC-β promotes the termination of Gq-GPCR signaling 
complexes by stimulating GTP hydrolysis of the GTP-bound Gq (Harden et al., 2011). 
While PLC-β has been thought of as being the canonical Gq effector, evidence from the 
last decade has shown that Gq-GPCRs are also potent activators of p63RhoGEF (Rojas et al., 
2007; Lutz et al., 2005). Northern blot analysis and immunohistochemistry suggest that 
p63RhoGEF is expressed in human heart and brain tissue (Lutz et al., 2004; Souchet et al., 
2002). Several groups of investigators have shown that p63RhoGEF activates the small 
GTPase RhoA, but not Rac1 or CDC42 (Lutz et al., 2004; Souchet et al., 2002). 
Astrocytes express GPCRs that signal through all four classes of Gα proteins. Astrocyte 
signaling via three of those classes— Gs, Gi, and G12/13-coupled GPCRs— is poorly 
understood. Astrocytic Gq-GPCRs have been the most extensively studied because of the 
early development of calcium indicator dyes that allow the monitoring of cytoplasmic 
calcium concentrations in real time (Tsien, 1988). 
Unlike neurons, astrocytes are electrically non-excitable. Instead, they employ a range 
of second messengers, including calcium, in their signaling cascades (Cornell-Bell et al., 
1990b). In 1996, Porter and McCarthy demonstrated that hippocampal astrocytes respond to 
synaptically released glutamate with calcium increases (Porter and McCarthy, 1996). 
Astrocytes not only respond to neuronal activity; they modulate neuronal activity via calcium 
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elevations that cause the release of gliotransmitters including ATP (Guthrie et al., 1999), 
glutamate (Parpura et al., 1994), and D-serine (Schell et al., 1995). 
Astrocytic release of gliotransmitters has been proposed to modulate several forms of 
synaptic transmission including heterosynaptic depression, inhibitory neurotransmission, and 
Long Term Potentiation (LTP, the sustained enhancement of excitatory synaptic transmission 
associated with memory and learning (Bliss and Lomo, 1973; Pascual et al., 2005; Kang et 
al., 1998). Astrocyte-mediated heterosynaptic depression has been suggested to occur in the 
hippocampus (Zhang et al., 2003). High frequency stimulation of the Schaffer collateral-
pyramidal neuron synapse induces calcium increases in an interposed astrocyte, which then 
releases ATP. ATP is converted to adenosine, which binds presynaptic adenosine A1 
receptors at a neighboring synapse, causing heterosynaptic depression. 
Astrocytes also have been reported to potentiate inhibitory synaptic transmission in the 
hippocampus (Kang et al., 1998). GABA release from inhibitory neurons binds GABAB 
receptors on astrocytes. This increases astrocytic calcium and causes astrocytes to release 
glutamate onto the GABAergic interneuron, increasing inhibitory drive. 
Hippocampal LTP depends on activation of post-synaptic N-methyl-D-aspartic acid 
(NMDA) receptors in the presence of a co-agonist— either glycine or D-serine (Johnson and 
Ascher, 1987; Bashir et al., 1990). LTP induction in the hippocampus and somatosensory 
cortex may depend on astrocyte calcium increases stimulating the release of D-serine 
(Henneberger et al., 2010; Takata et al., 2011). 
Despite these findings, gliotransmission is a controversial issue. Our lab has published 
several papers that question whether gliotransmission occurs under physiological conditions 
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(Agulhon et al., 2010; Fiacco et al., 2007; Petravicz et al., 2008). Figure 1 shows the tripartite 
synapse and astrocytic release of gliotransmitters. 
Astrocyte calcium increases have also been linked to control of cerebrovascular tone 
(Straub and Nelson, 2007). Over a century ago, Sherrington posited the notion of functional 
hyperemia: the coupling of temporal and spatial regulation of blood flow to support neuronal 
activity (Roy and Sherrington, 1890). Astrocytes are well-positioned to modulate blood flow 
in the CNS due to their extensive contacts with the vasculature (Newman, 1986). Moreover, 
the purinergic Gq-coupled GPCRs, P2Y2 and P2Y4 are highly expressed at astrocyte endfeet 
(Simard et al., 2003). Arteriole dilation triggered by neuronal activity depends on astrocyte 
calcium increases (Zonta et al., 2003). A major caveat of research linking astrocyte calcium 
increases to gliotransmission and modulation of the cerebrovasculature is the difficulty in 
selectively stimulating astrocyte Gq-GPCR signaling pathways. 
Astrocytes and neurons express many of the same GPCRs. As a result, conventional Gq-
GPCR ligands stimulate calcium increases in both neurons and astrocytes. Alternate 
approaches for stimulating astrocyte calcium include mechanical stimulation, electrical 
stimulation, or uncaging caged calcium or IP3 (Fiacco et al., 2009). All of these approaches 
have serious limitations. Neither mechanical nor electrical stimulation are physiological 
stimuli. Likewise, uncaging calcium or IP3 bypasses the endogenous Gq-GPCR signaling 
pathways. To address the role of astrocyte Gq-GPCR signaling pathways in physiology, we 
have developed new genetic mouse models that allow the selective stimulation of glial Gq-
GPCRs. In chapter 4, I will describe the development of this novel tool. 
 
CHAPTER 2.  
OVERVIEW OF PAIN AND ITCH BIOLOGY 
2.1. ANATOMY OF THE PAIN AND ITCH PROCESSING SYSTEM 
Pain and itch (pruritus) are both noxious sensory perceptions that alert an organism to 
potential harm. More than 2,300 years ago, Aristotle argued that the heart is the seat of 
emotions, including pain (Aristotle, 350 BCE). Descartes’ reflex theory, the first 
neurobiological model for pain processing, (Descartes, 1972) posited that painful stimuli 
activate a linear pathway that terminates in the brain where pain is perceived. 
Descartes’ theory was the dominant paradigm for more than 330 years until Melzack 
and Wall proposed their revolutionary “gate control” theory (Melzack and Wall, 1965). Gate 
theory states that pain perception is based on the operation of a neural gate in the dorsal horn 
whose opening is determined by the balance between noxious and innocuous input from the 
periphery. Melzack and Wall also recognized that there is dynamic regulation within and 
between the periphery, spinal cord, and supraspinal regions. 
Painful stimuli elicit a withdrawal response whereas itch elicits a scratch response. It 
has long been known that scratching blocks the sensation of itch, but the mechanism by 
which this occurs has only recently been discovered. Itch is a distinct sensory phenomenon 
from pain, but has a large degree of overlap with pain in its anatomical basis. 
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2.1.1. The peripheral pain and itch neurocircuitry. 
Sensory information is conveyed from the periphery to the spinal cord by primary 
afferents, which have their cell bodies in dorsal root ganglia (DRG). Primary afferents 
comprise three major classes: Aα/Aβ, Aδ, and C fibers. Aα/Aβ fibers are fast conducting, 
heavily myelinated, and generally convey innocuous and proprioceptive sensory information 
(Djouhri et al., 1998). Aβ fibers are low-threshold mechanoreceptors that are activated by 
gentle touch (Todd, 2010). 
In 1906, Sherrington conceived the idea of “specialized detectors” for pain, or 
nociceptors (Sherrington, 1906). Nociceptors fall into two major categories: Aδ fibers and C 
fibers (COLLINS et al., 1960). Aδ fibers are lightly myelinated and conduct more rapidly 
than unmyelinated C fibers (Burgess and Perl, 1967). Aδ fibers convey cold pain, mechanical 
pain, and well-localized pain sensations whereas C fibers are polymodal responding to 
noxious heat, mechanical, and chemical stimuli (DeLeo, 2006). C fibers can be further 
divided into peptidergic and non-peptidergic subtypes (Lawson et al., 1997; Snider and 
McMahon, 1998). Peptidergic C fibers contain neuropeptides such as substance P (Lawson et 
al., 1997); they innervate deep layers of the skin as well as other tissues (Bennett et al., 1996; 
Perry and Lawson, 1998). Non-peptidergic C fibers are restricted to the epidermis (Taylor et 
al., 2009). 
Nociceptors innervate sites throughout the body including skin, muscle, joints, and 
viscera (Julius and Basbaum, 2001). By contrast, itch is a dermatological phenomenon and, 
itch-sensing fibers are restricted to the skin. The sensation of itch is transmitted by a subset 
of mechanically insensitive, very slowly conducting C fibers (Schmelz et al., 1997). Both 
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nociceptors and pruritoceptors (itch-sensing primary afferents) have their central projections 
in the dorsal horn of the spinal cord, a central hub of sensory processing. 
2.1.2. The dorsal horn of spinal cord. 
Sensory information is processed in the spinal cord dorsal horn whereas the ventral horn 
contains motor neurons. The spinal cord is a laminated structure; the grey matter is divided 
into ten laminae. The dorsal horn contains laminae I-V whereas the ventral horn contains 
lamina VI-X (REXED, 1952). Lamina I and II compose the superficial dorsal horn. Lamina 
II is often subdivided into inner and outer sections (lamina IIi and IIo). 
Primary afferents have their central terminations in the dorsal horn. Aβ fibers are low-
threshold mechanoreceptors that arborize in lamina III-lamina V (Todd, 2010). Peripheral 
nociceptors terminate in lamina I and lamina II (also known as the marginal zone and the 
substantia gelatinosa, respectively) and lamina V (Kumazawa and Perl, 1978). More 
specifically, Aδ fibers terminate in lamina I, IIo, and V. Peptidergic C fibers terminate in 
lamina IIo, and non-peptidergic C fibers terminate in lamina II (Lawson et al., 1997; Light 
and Perl, 1979a; Lorenzo et al., 2008). Gastrin-releasing peptide receptor (GRPR) is 
restricted to lamina I and has been shown to mediate itch sensation in the spinal cord (Sun 
and Chen, 2007). 
The vast majority of neurons in the dorsal horn are interneurons: neurons whose axons 
remain in the spinal cord and arborize locally. Dorsal horn interneurons respond to a variety 
of stimuli. Wide dynamic range (WDR) neurons respond to noxious and innocuous stimuli 
whereas nociceptive-specific (NS) neurons selectively respond to potentially tissue-damaging 
stimuli (Price et al., 2003). Histamine, a classic pruritogen, also activates WDR neurons in 
the dorsal horn (Carstens, 1997). NS neurons dominate in the superficial dorsal horn whereas 
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WDR neurons comprise the majority of lamina V neurons (Willis, 1985). Lamina II contains 
a high density of both excitatory and inhibitory interneurons (Todd, 2010; Moore et al., 
2002). The inhibitory interneurons use GABA and/or glycine as inhibitory neurotransmitters. 
The interneurons of the dorsal horn vary widely in their morphology and their 
electrophysiological properties, making them difficult to classify. Perl and colleagues 
developed the most widely accepted classification scheme for lamina II interneurons (Grudt 
and Perl, 2002; Hantman et al., 2004; Lu and Perl, 2003; Lu and Perl, 2005). They identified 
four classes of interneurons: islet, central, vertical, and radial. This classification scheme still 
leaves roughly 30% of interneurons as being “unclassified,” which further illustrates the 
complexity of this region (Grudt and Perl, 2002). Lamina I contains both interneurons— 
which have been categorized based on morphology into pyramidal, fusiform, and multipolar 
categories— and projection neurons (Han et al., 1998). 
The dorsal horn receives sensory information from the periphery and transmits it to 
supraspinal sites via projection neurons. The majority of projection neurons reside in lamina I 
with a few scattered across laminae III-VI (Todd, 2010). Most projection neurons have axons 
that cross the midline to terminate in contralateral supraspinal structures. There are three 
major pain-selective ascending pathways from the dorsal horn: spinothalamic (to the 
thalamus and then on to the cortex), spinoreticular (to the medulla and pons), and 
spinomesencephalic (to the periaqueductal grey (PAG)) (Tracey and Dickenson, 2012). 
Lamina I also contains spinothalamic projection neurons that are selectively sensitive to 
histamine (Andrew and Craig, 2001). 
Pain and itch can be reduced by counter-stimuli. For example, a person might rub his 
arm after bumping his “funny bone” or put ice on burned skin. Counter-stimuli, such as 
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scratching, heat, cold, and pain-inducing chemicals, can inhibit itch in humans (Ross, 2011). 
Conversely, inhibition of nociceptors with opiates can cause itch (Ballantyne et al., 1988). 
Painful stimuli override itch-inducing stimuli; this seems favorable from an evolutionary 
standpoint, since pain-generating stimuli can cause massive tissue damage much faster than 
most itch-generating stimuli. 
The inhibition of itch by counter-stimuli occurs within the spinal cord dorsal horn since 
counter-stimuli inhibit itch even when applied outside the receptive field of the activated 
pruritoceptors (Nilsson et al., 1997). Scratching activates nociceptors, which synapse on 
spinal interneurons. These interneurons then inhibit itch spinothalamic projection neurons 
(Ross et al., 2010; Davidson et al., 2009). 
2.1.3. Supraspinal processing of pain and itch. 
Most of our knowledge about how the brain processes noxious stimuli is derived from 
functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) 
studies. While the PNS and spinal cord transmit noxious sensory information, supraspinal 
structures ultimately create the sensation of pain or itch. Supraspinal processing of pain and 
itch show large degrees of overlap. There are sensory-discriminative and affective-
motivational components to both pain and itch perception. 
Incoming sensory information from the spinal cord is relayed first to the thalamus and 
then to cortical regions. Lateral thalamic nuclei send projections to the somatosensory cortex 
where the spatial, temporal, and intensity aspects of pain and itch are processed (Tracey and 
Dickenson, 2012). Medial thalamic nuclei send projections to the anterior cingulate cortex 
(ACC) and to the insular cortex where the aversive aspect of pain and itch is processed 
(Vogt, 2005). 
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Imaging studies reveal that pain and itch stimuli cause activation of the prefrontal 
cortex (PFC) (Hsieh et al., 1994; Kwan et al., 2000; Moulton et al., 2005). The PFC has been 
linked to attention as well as to preparation of the motor response (Pardo et al., 1991). Both 
pain and itch activate the premotor area (PMA) and the supplementary motor area (SMA) 
(Hsieh et al., 1994; Kwan et al., 2000; Moulton et al., 2005), yet they generate distinct motor 
responses. Pain causes withdrawal, whereas itch generates scratching. Motor areas control 
movement on the contralateral side of the body. Hence, pain activates contralateral SMA to 
cause withdrawal and itch activates ipsilateral SMA to cause scratching (Hsieh et al., 1994). 
Pain and itch differentially activate the somatosensory cortex; pain activates the primary and 
secondary somatosensory cortices (S1 and S2) whereas itch only activates S1 (Ikoma et al., 
2006). 
2.1.4. Descending modulation. 
Primary afferents transmit noxious sensory information from the periphery to ascending 
pathways. Supraspinal structures can likewise modulate incoming sensory information 
through a process called descending modulation. For example, descending inhibition occurs 
in badly injured soldiers who do not appear to be in pain while on the battlefield, only to start 
complaining about pain after being taken to a hospital. Descending modulatory pathways can 
also facilitate pain perception (Fields, 2004). 
Descending modulation employs two major pathways (Fields, 2004). In the first, the 
ACC sends projections first to the PFC and then to the PAG. The second pathway directs 
input from the insula cortex to the PAG. The PAG then sends projections to the rostral 
ventromedial medulla (RVM), which transmits those projections via the spinal cord 
dorsolateral funiculus to the dorsal horn (North and Yoshimura, 1984). While descending 
 21 
modulation was first discovered in the 1960s in relation to nociception (Wall, 1967), it also 
modulates itch processing. For example, stimulation of the PAG suppresses histamine-
evoked responses in WDR neurons in the dorsal horn (Carstens, 1997). In conclusion, pain 
and itch perception arise from the summation of complex ascending and descending 
peripheral, spinal, and supraspinal neurocircuitry. Understanding the anatomical basis of pain 
and itch processing provides insight into the changes that occur in pathological pain and itch 
states. 
2.2. HOW DO ACUTE PAIN AND ITCH DIFFER FROM CHRONIC PAIN AND ITCH? 
2.2.1. Acute pain and itch are adaptive. 
Our pain and itch sensing systems have evolved to protect us from possible threats. 
Aristotle reportedly said that, “we cannot learn without pain.” Mutations in genes critical to 
the normal development and/or functioning of pain neurocircuitry can result in congenital 
insensitivity to pain (CIP) (Cox et al., 2006). Patients with this disorder suffer repeated 
injuries due to painless tissue damage (Sandroni et al., 2006). Most CIP patients do not live 
past childhood due to neglect of injuries and illnesses (Nagasako et al., 2003). These severe 
impairments highlight how important normal processing of noxious stimuli is for survival. 
2.2.2. Chronic pain and itch are pathological. 
While acute pain and itch perception is beneficial, chronic pain and itch do not serve 
any purpose and cause great suffering to patients. Acute pain and itch alert an organism to 
the presence of a potential threat. By contrast, chronic pain and itch can occur in the absence 
of any noxious stimuli. Chronic pain and chronic itch both involve long-term changes at the 
cellular and molecular levels in both the PNS and CNS. 
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PNS plasticity that leads to hypersensitivity is called peripheral sensitization. 
Inflammatory mediators, bradykinin, serotonin (5-HT), and prostaglandin, can all induce 
peripheral sensitization in both chronic pain and itch (Ikoma et al., 2006). Nerve growth 
factor (NGF), a neurotrophin, is upregulated in chronic pain syndromes such as vulvar 
vestibulitis and in chronic itch conditions such as atopic dermatitis (AD) (Bohm-Starke et al., 
1998; Hefti et al., 2006). NGF induces peripheral sensitization by causing sprouting of 
nociceptors and pruritoceptors (Bohm-Starke et al., 1998; Urashima and Mihara, 1998).  
Another mechanism for peripheral sensitization is alterations in the subcellular 
localization of voltage-gated sodium channels. Voltage-gated sodium channels generate and 
conduct action potentials in neurons (Dib-Hajj et al., 2009). Injury to peripheral nerves can 
lead to redistribution of tetrodotoxin-resistant voltage-gated sodium channels in nociceptors 
from the soma to the site of axonal injury (Novakovic et al., 1998). This has been linked to 
hyperactivity and abnormal spontaneous activity in human nociceptors (Ochoa et al., 1982). 
CNS plasticity that leads to enhanced pain and itch is called central sensitization. 
Homeostasis depends on the balance of excitatory and inhibitory neurotransmission. 
Hyperexcitability at glutamatergic synapses in lamina II has been observed in animal models 
of neuropathic pain (Balasubramanyan et al., 2006). In addition, activation of silent 
glutamatergic synapses in the superficial dorsal horn has been linked to chronic pain (Li and 
Zhuo, 1998). 
Decreases in inhibitory neurotransmission in the CNS can also lead to central 
sensitization. Tonic GABA tone is required for homeostasis, and intrathecal injection of the 
GABAA antagonist, bicuculline, produces thermal hyperalgesia and mechanical allodynia in 
naïve rats (Malan et al., 2002). Hence, losing GABAergic inhibitory tone in lamina II can 
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contribute to enhanced pain sensitivity in patients with neuropathic pain (Moore et al., 2002; 
Malan et al., 2002; Yamamoto and Yaksh, 1993). 
Several mechanisms have been proposed to explain diminished GABAergic tone during 
neuropathic pain. Decreased levels of glutamate decarboxylase 65 (GAD65), a rate-limiting 
enzyme for GABA synthesis, were detected in the dorsal horn of rats that had undergone two 
models of neuropathic pain: CCI (chronic constriction injury) and SNI (spared nerve injury) 
(Moore et al., 2002). Changes in GAD expression could affect presynaptic GABA levels. 
Dorsal horn GABA levels appear to decrease in rats with CCI as compared to sham-operated 
rats (Ibuki et al., 1997). In addition, CCI reduces excitatory drive to and membrane 
excitability of GABAergic tonic central cells in rats (Balasubramanyan et al., 2006). Loss of 
inhibitory neurons in the dorsal horn could also contribute to chronic itch. Mice lacking the 
transcription factor Bhlhb5 show a selective loss of inhibitory interneurons in the spinal cord 
and show abnormally heightened itch (Ross et al., 2010). 
2.2.3. Traits of chronic pain and itch. 
The International Association for the Study of Pain defines chronic pain as “pain that 
persists past the healing phase following an injury” (Merskey and Bogduk, 1994). Clinicians 
generally consider itch and/or pain to be chronic when it lasts for at least three to six months 
(Ikoma et al., 2006; Verhaak et al., 1998). Chronic pain and itch have very different 
phenotypes than acute pain and itch.  
The psychophysical traits of chronic pain and itch can be subdivided into spontaneous 
and evoked categories. Ectopic C fiber activity and the sensitization of dorsal horn neurons 
are thought to cause spontaneous pain (Woolf and Mannion, 1999). Patients assess 
spontaneous pain and itch through self-reported rating scales. The Visual Analog Scale 
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(VAS), which rates pain along a continuum (usually from 0-10) (Scott and Huskisson, 1976), 
is one of the most common clinically used measures of pain due to its simplicity (Carlsson, 
1983). 
The VAS is limited primarily by its inability to either describe pain quality or detect 
changes in pain quality over time (Elman et al., 2010). Pain has a range of qualities that 
cluster in three major categories: paroxysmal (shooting, sharp, and radiating), superficial 
(cold, sensitive, tingling) and deep (aching, throbbing, cramping) (Victor et al., 2008). To 
address these limitations, questionnaires that measure pain qualities have been developed. 
The McGill Pain Questionnaire (MPQ) was the first comprehensive pain quality measure 
(Melzack, 1975); it measured intensity, temporal qualities, spatial location, and sensory and 
affective qualities. Measurements of spontaneous pain are usually restricted to humans since 
animals obviously cannot speak. However, Mogil and colleagues have developed an 
intriguing measure of spontaneous pain in rodents, the “Grimace Scale,” which quantifies 
pain using facial expressions (Langford et al., 2010; Sotocinal et al., 2011). Figure 2 shows 
the Rat Grimace Scale. 
Itch, like pain, is a multidimensional, subjective experience and therefore faces similar 
measurement challenges. Again, the VAS is widely used to measure itch, but the limitations 
it faces in measuring itch are similar to those limiting its use in measuring pain (Elman et al., 
2010). For adult patients, the 5-D Pruritus Scale is a validated measurement tool; the “5 Ds” 
are duration, degree, direction, disability, and distribution (Elman et al., 2010). The Itch Man 
Scale, developed for use in pediatric patients, measures both itch severity and impact on 
quality of life through a series of cartoons (Figure 3) which show the “Itch Man” becoming 
increasingly itchy and distressed (Blakeney and Marvin, 2000). 
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Studies of humans measure evoked pain and itch as well as spontaneous pain and itch. 
Evoked measures of thermal and mechanical sensitivity have the benefit of being objective 
measurements as opposed to the strictly subjective measurements of spontaneous pain and 
itch. Evoked pain and itch are the chief tools for measuring noxious sensory processing in 
laboratory animals. 
Evoked responses to both mechanical and thermal pain are usually measured to find the 
threshold at which mechanical, hot and cold stimuli are perceived as noxious. Mechanical 
allodynia and hyperalgesia are hallmarks of chronic pain patients. The former is the 
perception of a formerly non-noxious mechanical stimulus as being noxious; the latter is an 
exaggerated reaction to a painful thermal or mechanical stimulus. Central sensitization is 
thought to cause both allodynia and hyperalgesia. Allodynia is generated by low-threshold 
nociceptors or Aβ fibers (Woolf and Mannion, 1999; Sandkuhler, 2009). Hyperalgesia is 
thought to be due to sensitization of peripheral nociceptors (Sandkuhler, 2009). 
Chronic itch also has patterns of central sensitization; these patterns result in 
phenotypes analogous to that observed in chronic pain. Alloknesis, the itch analogue of 
allodynia, is when innocuous touch triggers itch (Ikoma et al., 2006). Hyperknesis— the itch 
analogue of hyperalgesia— is an exaggerated itch reaction evoked by mechanical stimuli 
(Atanassoff et al., 1999). Acute itch is a common sensation relieved by scratching. By 
contrast, scratching does not alleviate chronic itch; indeed, it exacerbates the problem by 
causing tissue damage (Yosipovitch et al., 2003). 
2.2.4. Major categories of chronic pain and itch. 
A broad range of conditions can result in chronic pain and itch. The major categories for 
chronic pain are determined by the site of injury (back, head, viscera) or the type of injury 
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(cancer, neuropathic, inflammatory, arthritis) (Apkarian et al., 2009). Damage to the nervous 
system – either centrally or peripherally- can result in neuropathic pain (Woolf and Mannion, 
1999). A range of nervous system injuries, caused by such things as trauma, stroke, infection, 
diabetes, autoimmune disease and exposure to chemotherapeutic agents, can all result in 
neuropathic pain (Ji and Strichartz, 2004; Campbell and Meyer, 2006). 
Chronic itch is also a heterogeneous disease caused by a broad spectrum of pathologies. 
Clinically, chronic itch can be subdivided into itch caused by skin disorders, itch caused by 
systemic disorders, neuropathic itch, and psychogenic itch. Skin disorders that can cause itch 
include atopic dermatitis (AD), psoriasis and parasitic infections (Ikoma et al., 2006). While 
itch is a skin sensation, dysfunction of other organ systems can cause chronic itch. Systemic 
disorders such as renal failure, hyperthyroidism, lymphoma, cholestasis (a chronic gall 
bladder disease), solid tumors and HIV/AIDS can cause chronic itch (Twycross et al., 2003). 
The same sorts of nervous system injury that result in neuropathic pain can also cause 
neuropathic itch (Yosipovitch et al., 2003). Psychogenic itch can be generated by delusions 
of parasitosis, stress, and depression (Ikoma et al., 2006). Understanding the clinical aspects 
of chronic pain and itch is essential to make the proper diagnosis and to prescribe appropriate 
treatments. 
2.3. DIAGNOSIS AND TREATMENT 
2.3.1. How are chronic pain and itch diagnosed? 
The first step in diagnosing chronic pain and itch is to obtain a patient history and a 
detailed description of spontaneous pain and/or itch using a validated questionnaire 
(Yosipovitch et al., 2003). Next, a full physical examination including testing of reflexes and 
motor skills should be performed (Harden, 2005). Another important diagnostic tool is 
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sensory testing. These tests include measurements of mechanical, heat pain, and cold pain 
thresholds (Oaklander et al., 2002). 
Small-fiber polyneuropathy (SFPN) refers to damage to the axons of Aδ fibers and C 
fibers (Oaklander, 2011). It is a common cause of neuropathic pain and neuropathic itch 
(Mendell and Sahenk, 2003). The American Academy of Neurology endorses two tests to 
diagnose SFPN: distal-leg skin biopsies and autonomic-function testing (England et al., 
2009). Skin biopsies are stained with the panaxonal marker anti-PGP9.5 in order to quantify 
small cutaneous sensory fibers; patients with SFPN have a reduced density of intra-epidermal 
fibers compared to controls (McCarthy et al., 1995) Autonomic-function testing is used 
because autonomic nervous system deficits such as anhidrosis (the inability to sweat 
normally) have strong predictive value for SFPN (Low et al., 2006). 
2.3.2. Statistics and costs to treat chronic pain and itch. 
Chronic pain has tremendous costs to society in addition to the toll it exacts on patients. 
Chronic pain has been estimated to affect one-sixth of the population (Campbell and Meyer, 
2006). Neuropathic pain, caused by damage to the nervous system, accounts for an estimated 
3.5 million cases in the United States alone (Harden, 2005). Chronic inflammatory pain is 
also a major public health issue. For example, osteoarthritis is a leading cause of disability 
worldwide (Sharma et al., 2006). In the United States workforce, lost productivity due to 
chronic pain conditions is estimated to cost $61.2 billion per year (Stewart et al., 2003). 
Chronic itch also places a large burden on society, both in terms of cost and human 
suffering. Chronic itch has been estimated to occur in 50-90% of patients with renal or liver 
disease and in patients with severe burns, AD, and other dermatological diseases (Carstens, 
2008). The global prevalence of AD in children has been estimated at 20%, and it has an 
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annual cost of almost $1 billion in the United States alone (Carroll et al., 2005). The best-
known complication of herpes zoster (shingles) is postherpetic neuralgia (PHN), a type of 
neuropathic pain. Postherpetic itch (PHI), a type of neuropathic itch, has been reported to 
occur in 17-58% of postherpetic patients instead of or accompanying PHN (Oaklander et al., 
2003). Both chronic pain and itch create additional suffering due to the inadequacy of current 
treatments. 
2.3.3. Major classes of analgesics and antipruritics. 
Pharmacological treatment is the mainstay for managing chronic pain. The first drugs 
developed to treat pain came from serendipitous observations of analgesic properties of 
plants.  Opioids were first derived from the poppy and salicylic acid, an early non-steroidal 
anti-inflammatory drug (NSAID), was extracted from willow bark (Scholz and Woolf, 2002). 
The use of opioids is limited by sedation as well as the risk for addiction and the 
development of opioid-induced hyperalgesia, a state of heightened pain sensitivity (Mendell 
and Sahenk, 2003; Hartrick et al., 2012). Since pain is known to inhibit itch, opioid treatment 
can cause uncontrollable itchiness (Ballantyne et al., 1988). Further evidence implicating 
opioidergic neurotransmission in itch comes from patients with chronic itch due to liver 
disease. These patients have abnormally high levels of endogenous opioids (Swain et al., 
1992), and they experience reduced scratching following treatment with the opioid receptor 
antagonist, naloxone (Jones et al., 2002). A recent study suggests that opioid-induced itch 
occurs when the mu-opioid receptor, MOR1D, heterodimerizes with GRPR in the spinal cord 
to relay itch information (Liu et al., 2011). Inhibiting downstream signaling effectors of 
GRPR blocked morphine-induced itch while preserving morphine-induced analgesia thus 
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demonstrating that selective targeting of MOR isoforms might preserve the analgesic effects 
of opioids while bypassing the side effect of itchiness (Liu et al., 2011). 
Patients with neuropathic pain do not respond to NSAIDs and are often insensitive to 
opioids (Woolf and Mannion, 1999). Neuropathic pain is treated primarily with 
antidepressants (selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants) 
and anticonvulsants, including gabapentin (Carter and Galer, 2001). These drugs have limited 
efficacy and often undesired side effects (Woolf and Mannion, 1999; Kingery, 1997). 
Unlike acute itch, neuropathic itch is resistant to treatment with antihistamines, 
corticosteroids, and most pain medications (Oaklander, 2011). Scratching in chronic itch 
patients can often cause severe tissue damage; one patient with PHI eventually scratched 
through her own skull (Oaklander et al., 2002). Surprisingly, some chronic itch patients may 
not understand that their skin lesions are due to their scratching. Patient education therefore 
can be an important intervention. Some patients use protective garments to protect their skin 
from involuntary scratching during sleep (Oaklander, 2011). 
Capsaicin, the active ingredient in chili peppers, has been shown to be an effective 
treatment for the itch of AD (Yosipovitch et al., 2003). However, it also produces irritation at 
the site of application, which reduces patient compliance. Local anesthetics such as lidocaine 
that block selectively pruritoceptor firing can be beneficial (Oaklander, 2011; Fishman et al., 
1997). 
Clearly, chronic pain and itch patients would benefit greatly from the development of 
more effective treatments. Historically, pain and itch research has been neurocentric. During 
the last two decades, a role for glia in pain modulation has been uncovered and may provide 
future potential therapeutic targets. 
CHAPTER 3.  
THE EVOLVING ROLE OF GLIA IN PAIN MODULATION. 
3.1. ARE GLIA “GOOD GUYS OR BAD GUYS” IN THE SETTING OF CHRONIC PAIN? 
3.1.1. The role of astrocytes in chronic pain. 
Pain researchers have traditionally focused on neurons, since they transmit nociceptive 
sensory information. But, a growing body of research implicates glia in the development and 
maintenance of chronic pain. While there are other types of glia (microglia, 
oligodendrocytes, NG2 glia, Schwann cells), our focus is on the role that astrocytes, satellite 
glial cells (SGCs), and non-myelinating Schwann cells play in chronic pain. Astrocytes are 
present throughout the spinal cord and brain. In the PNS, SGCs surround the cell bodies of 
sensory neurons in DRG, while non-myelinating Schwann cells contact the axons of C fibers. 
The glial marker GFAP is expressed by astrocytes, SGCs, and non-myelinating Schwann 
cells. 
Many neurological diseases cause astrocytes to become reactive, a process also known 
as astrogliosis. Reactive astrocytes exhibit cellular hypertrophy and increased levels of GFAP 
(Figure 5) (Hansson, 2006). Garrison and coworkers were the first to show that inducing 
chronic pain in adult rats causes astrogliosis in the ipsilateral dorsal horn of the spinal cord 
(Garrison et al., 1994) while the contralateral astrocytes remain quiescent. Since then, a range 
of chronic pain models including peripheral nerve injury, inflammation, and tumor invasion 
have been shown to cause astrogliosis (Gao and Ji, 2010; Colburn et al., 1999; Raghavendra 
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et al., 2004). In addition, chronic pain causes astrogliosis at supraspinal sites. For example, 
CCI causes astrogliosis in the RVM, whereas injection of complete Freund’s adjuvant (CFA) 
—an inflammatory agent— causes astrogliosis in the forebrain (Raghavendra et al., 2004; 
Guo et al., 2007; Wei et al., 2008). However, most studies of astrogliosis have focused on the 
spinal dorsal horn since it is an extensively studied site of nociceptive processing. 
It has been demonstrated that blocking astrogliosis also prevents chronic pain. For 
example, both fluoroacetate and its metabolite fluorocitrate are selectively taken up by glia 
and are general inhibitors of astrocytes (Gao and Ji, 2010; Largo et al., 1997). Fluoroacetate 
and fluorocitrate attenuate metabolic activity in astrocytes by interfering with ATP 
production in the Krebs cycle (Hassel et al., 1992). Intrathecal administration of fluorocitrate 
blocks thermal and mechanical hyperalgesia in an inflammatory pain model (Meller et al., 
1994) as well as in a mirror-image neuropathic pain model (Milligan et al., 2003). L-α-
aminoadipate— a homolog of glutamate that naturally occurs in the brain— has also been 
proposed as an astrocyte-selective inhibitor (Huck et al., 1984; Khurgel et al., 1996). 
Intrathecal administration of L-α-aminoadipate reversed mechanical allodynia generated by 
spinal nerve ligation (SNL), a model of chronic neuropathic pain (Zhuang et al., 2006). 
While these observations that inhibition of astrocytes could block chronic pain were made 
more than twenty years ago, only in the past decade have researchers found evidence for 
specific glial mediators of chronic pain. 
Tissue or nerve injury results in the release of various neurotransmitters and 
inflammatory mediators— including ATP, glutamate, and tumor necrosis factor-alpha (TNF-
α)— which go on to activate spinal cord astrocytes (Gao and Ji, 2010). Reactive astrocytes 
then activate several intracellular signaling pathways including the c-Jun N-terminal kinase 
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(JNK) and extracellular signal-related kinase (ERK) pathways (Zhuang et al., 2005; Ma and 
Quirion, 2002; Gao et al., 2009). Finally, astrocytic JNK and ERK activation leads to the 
release of inflammatory cytokines and chemokines, which cause hypersensitivity in pain 
processing pathways. 
Spinal cord astrocytes upregulate interleukin-1 beta (IL-1β)— an inflammatory 
cytokine— in several pain conditions including bone cancer, nerve injury, and masseter 
inflammation (Guo et al., 2007; Wei et al., 2008; Zhang et al., 2005). In addition, intrathecal 
injection of IL-1β is sufficient to generate pain hypersensitivity (Kawasaki et al., 2008b). The 
IL-1 receptor colocalizes with neuronal NMDA receptors in the spinal cord, trigeminal 
nucleus, and RVM (Guo et al., 2007; Wei et al., 2008; Zhang et al., 2008). Thus, IL-1β 
released from astrocytes can bind to neuronal receptors and directly modulate neuronal 
activity. In patch clamp studies of lamina II neurons in spinal cord slices, application of IL-
1β enhanced both the frequency and amplitude of NMDA-mediated spontaneous excitatory 
post-synaptic currents (sEPSCs) and decreased the frequency and amplitude of spontaneous 
inhibitory post-synaptic currents (Kawasaki et al., 2008a). This suggests that IL-1β causes 
central sensitization by increasing excitatory synaptic transmission and decreasing inhibitory 
synaptic transmission. 
The chemokine monocyte chemoattractant protein-1 (MCP-1, also called CCL2), which 
has also been implicated in astrocytic promotion of pain hypersensitivity, is upregulated in 
spinal cord astrocytes after SNL (Gao and Ji, 2010; Gao et al., 2009). CCR2 is the major 
receptor for MCP-1 (Abbadie et al., 2003), and nerve injury increases CCR2 expression in 
DRG and spinal cord neurons (Gao et al., 2009; White et al., 2005). MCP-1 potentiates 
glutamatergic synaptic transmission and inhibits GABAergic synaptic transmission in spinal 
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cord neurons, and thus may enhance central sensitization (Gao et al., 2009; Gosselin et al., 
2005). 
Changes in glutamate transporters have also been linked to the astrocyte-mediated 
enhancement of chronic pain states. Astrocytic glutamate transporters facilitate clearance of 
extracellular and synaptic glutamate in order to maintain homeostasis (Huang and Bergles, 
2004). Nerve injury causes an initial increase in astrocytic glutamate transporters, GLT-1 and 
GLAST, followed by a persistent decrease (Sung et al., 2003; Xin et al., 2009). While gene 
transfer of GLT-1 into the spinal cord of rats did not affect acute pain, transgenic GLT-1 was 
anti-nociceptive in chronic inflammatory and neuropathic pain models (Maeda et al., 2008). 
These data highlight the importance of astrocytic glutamate transporters and raise the 
possibility that they may be viable therapeutic targets. 
Finally, reactive astrocytes have been linked to the phenomenon of allodynia, a 
widespread and intractable symptom of neuropathic pain. The spinal cord has a tonic 
inhibitory tone due to the neurotransmitters, GABA and glycine (Willcockson et al., 1984). 
Acute intrathecal strychnine— a glycine receptor antagonist— results in morphine-
insensitive allodynia resembling the sensory abnormalities observed in neuropathic pain 
patients (Sherman and Loomis, 1994). Strychnine-evoked allodynia is blocked by the NMDA 
receptor antagonist, MK-801, suggesting that it depends on NMDA receptors (Yaksh, 1989). 
NMDA receptor activation requires binding by glutamate and its co-agonist, D-serine 
(Miraucourt et al., 2011). D-serine has also been shown to function as a gliotransmitter 
(Schell et al., 1995). Recent work shows that intrathecal strychnine blocks the spinal cord’s 
tonic inhibitory tone, which may result in touch-mediated astrogliosis. This potentially 
causes reactive astrocytes to then release D-serine, activating NMDA receptors and resulting 
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in allodynia (Miraucourt et al., 2011). Clearly, numerous mediators have been implicated in 
the ability for reactive astrocytes to enhance chronic pain states. More research is required to 
fully understand the role of astrocytes in chronic pain. 
3.1.2. The role of SGCs in chronic pain. 
The glial research community has emphasized the role of astrocytes in chronic pain. 
SGCs respond to both nerve injury and chronic compression of the DRG (CCD), an animal 
model of low back pain, in the same manner as astrocytes— by proliferating and 
upregulating GFAP (Elson et al., 2004; Zhang et al., 2009). SGCs appear to modulate 
chronic pain through changes in potassium buffering. 
Neuronal excitability is largely determined by the extracellular concentration of 
potassium ions (Orkand et al., 1966). Astrocytes and SGCs regulate the extracellular 
potassium concentration via the inward rectifying channel Kir4.1 (Takumi et al., 1995; Vit et 
al., 2006). CCD causes SGCs to exhibit decreased inwardly rectifying potassium currents, 
which leads to neuronal hyperexcitability (Zhang et al., 2009). In addition, peripheral nerve 
injury causes the downregulation of Kir4.1 in SGCs. Silencing Kir4.1 in the trigeminal 
ganglia of naïve rats leads to spontaneous and evoked facial pain (Vit et al., 2008). This 
suggests that potassium buffering by astrocytes and SGCs is crucial to maintaining 
homeostasis, and that it decreases in multiple models of chronic pain. 
3.2. THE LIMITATIONS OF CURRENT APPROACHES FOR STUDYING GLIA 
AND PAIN 
While the research to date has shed a great deal of light on the role of glia in chronic 
pain, previously used approaches have limitations. For instance, glial inhibitors such as 
fluorocitrate have been extensively used to show that blocking gliosis prevents the 
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development of chronic pain. However, these inhibitors are crude pharmacological tools; 
fluorocitrate is thought to disrupt both astrocytic and microglial metabolism (McMahon and 
Malcangio, 2009). Moreover, microglia have been shown to contribute to chronic pain states 
through the release of inflammatory cytokines. Current approaches lack the ability to 
distinguish the role of astrocytes in chronic pain from the roles of other glia. Finally, there is 
the “chicken and egg” problem: which came first, the chronic pain or the astrogliosis? 
Almost all current approaches involve inducing chronic pain and then measuring changes in 
astrocytes. Establishing that astrocytes are causal agents— rather than merely correlated— is 
difficult using this approach. In Chapter 4, we will show how our lab used a genetic approach 
to examine whether the Gq-DREADD (Designer Receptor Exclusively Activated by a 
Designer Drug) model can be used to selectively stimulate glial Gq-GPCRs and then measure 
changes in pain and itch sensitivity. 
 
CHAPTER 4.  
THE GQ-DREADD MOUSE MODEL CAN BE USED TO SELECTIVELY 
STIMULATE GQ-GPCR PATHWAYS IN GFAP+ GLIA. 
4.1. INTRODUCTION: DEVELOPMENT OF THE GQ-DREADD MOUSE MODEL 
Selective stimulation of astrocytic GPCRs is difficult because astrocytes and neurons 
often express overlapping subsets of receptors. As discussed in Chapter 1, previous 
approaches that have been used include conventional pharmacological agents, mechanical 
stimulation, and uncaging Ca2+or IP3 (Fiacco et al., 2009). All of these approaches are either 
non-physiological stimuli or lack astrocytic selectivity. Transgenic mouse models were 
developed as an improvement over these past techniques. 
The first engineered GPCRs were the RASSLs (Receptor Activated Solely by a 
Synthetic Ligand). The Ro1 RASSL is a modified human kappa-opioid receptor (KOR) with 
dramatically reduced affinity for the natural peptide ligand, but retained affinity for synthetic 
ligands such as spiradoline (Coward et al., 1998). Ro1 is a chimeric receptor of KOR 
containing the second extracellular loop of the delta-opioid receptor. Stimulation of Ro1 with 
spiradoline activates Gi-coupled signaling pathways. 
A tetracycline-inducible system was used to express Ro1 selectively in GFAP+ cells 
(Sweger et al., 2007). When such mice were taken off doxycycline, a tetracycline derivative, 
100% of the mice developed hydrocephalus (Sweger et al., 2007; McMullen et al., 2012). 
The fact that hydrocephalus developed without Ro1 stimulation with spiradoline is consistent 
with Ro1 having high levels of constitutive activity. While this was a powerful model for 
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studying the role of glia in hydrocephalus, the high basal RASSL activity was undesirable for 
studying GPCR pathways. Moreover, spiradoline is a KOR agonist; thus the Ro1 mouse 
model had to be maintained on a KOR knockout background. Ideally, an engineered receptor 
would be activated by a synthetic ligand that did not also activate endogenous GPCRs. 
The first transgenic mouse model that allowed the selective stimulation of astrocytic Gq-
GPCRs was the MrgA1 (Mas-related genes receptor A1) model (see Figure 6) (Fiacco et al., 
2007). The MrgA1 receptor is endogenously expressed in peripheral sensory neurons (Dong 
et al., 2001). Stimulation of MrgA1 with the Phe-Met-Arg-Phe (FMRF) peptide activates Gq-
coupled GPCR signaling pathways (Dong et al., 2001). 
Expression of the MrgA1 receptor in astrocytes is achieved by breeding a tetracycline-
regulated tet operon (tetO MrgA1) mouse to a transgenic mouse expressing an astrocyte-
selective tetracycline transactivator (GFAP tTA) line; expression of the MrgA1 protein 
occurs in the absence of tetracycline or doxycycline. A major advantage of this approach is 
that the timing of expression of MrgA1 can be easily controlled. Keeping the mice on 
doxycycline until post-natal day 30 avoids any possible phenotype due to transgenic MrgA1 
expression in the developing nervous system. Our laboratory showed that the MrgA1 peptide 
ligand, FMRF, selectively causes calcium increases in astrocytes, but not in neurons in 
acutely isolated hippocampus slices (Fiacco et al., 2007). 
While the MrgA1 model was a major technical advance for the glial biology field, no 
research tool is without limitations. The peptide, FMRF, does not cross the BBB. Thus, the 
MrgA1 model cannot be used for in vivo studies of astrocyte Gq-GPCR signaling pathways. 
Similarly, the MrgA1 model is not appropriate for pain or itch studies on peripheral GFAP+ 
glial Gq-GPCR signaling due to the endogenous receptors on peripheral nociceptors. 
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Because of these technical limitations, we turned to the recently developed DREADD 
(Designer Receptor Exclusively Activated by a Designer Drug) model (Armbruster et al., 
2007). The native M3 muscarinic acetylcholine receptor (M3AChR) is a Gq-coupled GPCR. 
M3AChR is activated by acetylcholine (ACh), but not the pharmacologically inert ligand, 
clozapine N-oxide (CNO). DREADD was engineered to respond to CNO, and not ACh using 
a directed molecular evolution approach in yeast (Armbruster et al., 2007). First, libraries of 
randomly mutated muscarinic receptors were created by mutagenic PCR. Then, yeast-
expressing mutant receptors activated by CNO were selected for growth on nutrient-deficient 
media and verified in liquid growth assays. Clones were retransformed into yeast and those 
with desirable properties were remutagenized for subsequent rounds of selection using lower 
concentrations of CNO to select for receptors with higher potency. The final mutant, 
DREADD (hM3D) has two point mutation in the 3rd and 5th transmembrane regions of the 
endogenous M3 muscarinic receptor (hM3): Y149C and A239G (Figure 7). Importantly, 
DREADD appears to have low basal activity in the absence of CNO. While DREADDs have 
been engineered that couple to Gαs, Gαi, and Gαq (Guettier et al., 2009), this dissertation will 
focus on the Gq-DREADD model. 
To determine the effect of the selective stimulation of glial Gq-GPCR signaling 
cascades on nociception and itch, we utilized a transgenic mouse line that expresses Gq-
DREADD under the control of the GFAP promoter. CNO crosses the BBB and lacks 
appreciable affinity for endogenous GPCRs (Armbruster et al., 2007). Selective activation of 
Gq-DREADD in vivo can be achieved easily by intraperitoneal injection of CNO. Our data 
strongly suggest that the Gq-DREADD mouse model allows selective stimulation of Gq-
GPCR signaling pathways in GFAP-positive glia. Both immunocytochemistry and calcium 
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imaging data show that Gq-DREADD is expressed in astrocytes and non-myelinating 
peripheral glial but not in neurons. Thus, this model is a powerful new tool for studying the 
role of glial signaling pathways in pain and itch transmission neurocircuitry. 
4.2. MATERIALS AND METHODS 
4.2.1. Generation of transgenic mice. 
To generate the Gq-DREADD mice, the coding sequence for Gq-DREADD (obtained 
courtesy of B. Roth lab, UNC-CH; (Armbruster et al., 2007) was placed downstream of β-
globin intron containing splice donor/acceptor sites and upstream of simian virus 40 (SV40) 
polyA sequence (intron and SV40 sequence are contained in pTg1 (courtesy of R. Thresher, 
UNC-CH)). The 2 kilobase (kB) human GFAP promoter (courtesy of M. Brenner, UA 
Birmingham) was cloned upstream of the intron. Gq-DREADD has a human influenza 
hemagglutinin (HA) epitope tag on the N terminus. The expression construct was isolated 
from prokaryotic sequence and injected into C57 × C3H hybrid oocytes by the Animal 
Models Core Facility at UNC-CH. Founder mice were identified by polymerase chain 
reaction (PCR), bred to C57/BL/6J mice and screened for transgene expression. Gq-
DREADD mice were then backcrossed with C57/BL6/6J mice for at least 7 generations 
before testing. 
The tdTomato protein (Shaner et al., 2004) was expressed in transgenic mice using 
standard molecular biology techniques. Briefly, the 2.2 kB human GFAP promoter was 
cloned upstream of a β-globin intron in pTg1. Then, the tdTomato sequence was excised 
from pdtTomato vector (Clontech) and cloned downstream of the β-globin intron. The polyA 
signal from SV40 followed the tdTomato sequence. Finally, GFAP-Tomato-pA was excised 
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from the vector and injected into fertilized oocytes. Founder mice were identified by PCR, 
bred to C57/BL/6J mice, and screened for transgene expression. 
Gq-DREADD mice were bred to GFAP-tdTomato mice, and GFAP-GFP mice (Zhuo et 
al., 1997). All mice were housed with a 12-h light-dark cycle and were given food and water 
ad libitum. Mice were kept in the animal facilities at the University of North Carolina, 
Chapel Hill in accordance with Institutional Animal Care and Use Committee guidelines. 
4.2.2. Calcium imaging. 
Acute transverse (500 µm) spinal cord slices were prepared from 10- to 17-day old 
GFAP-tdTomato and Gq-DREADD × GFAP-tdTomato mice. Briefly, the lumbar spinal cord 
was quickly removed from anesthetized mice and sectioned on a Leica VT1000s Vibratome 
(Bannockburn, IL) in oxygenated ice-cold slicing buffer containing (in millimolar (mM)): 75 
sucrose, 2.5 NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 0.5 CaCl2, 3.5 MgCl2, 1.3 ascorbic acid, 3 
pyruvate, and 0.1 kynurenic acid. The slices were incubated in oxygenated artificial 
cerebrospinal fluid (ACSF) containing (in mM): 125 NaCl, 10 glucose, 1.25 NaH2PO4 × 
H2O, 26 NaHCO3, 2.5 KCl, 2.5 CaCl2, 1.3 MgCl2, and 0.1 Trolox plus 0.07% pluronic acid 
and 11 µM calcium indicator fluo-4 AM at 37°C for 17 minutes and then at room 
temperature for 43 minutes. The slices were then washed in ACSF to remove unincorporated 
dye. Slices were then transferred to a recording chamber (Warner Instruments, Hamden, CT) 
of an upright microscope (Olympus, Melville, NY) and continuously perfused with 
oxygenated, room temperature ACSF containing 1µM tetrodotoxin (TTX). 
Calcium imaging was performed using a custom-made two-photon microscope. Two-
photon confocal microscopy was used to visualize fluo-4 and GFAP-Tomato-positive cells in 
laminae II and V. A Coherent (Santa Clara, CA) Chameleon Ultra Ti:sapphire diode-pumped 
 41 
laser was tuned to 830 nm to excite fluo-4 AM and 930 nm to excite tdTomato. A 525/50 
bandpass filter (Chroma) was used to detect fluo-4 AM, and a 620/52 bandpass filter 
(Chroma) was used to detect tdTomato. Images were acquired by using an Olympus (Tokyo, 
Japan) IR-LUMPlanFl water-immersion objective (60x; 0.9 numerical aperture). To monitor 
changes in fluorescence over time, Olympus Fluoview v.5 software was used to place region 
of interest (ROI) boxes over the soma of astrocytes. Increases in calcium concentration were 
measured as increases in average fluorescence intensity over baseline fluorescence (ΔF/F0) 
within the ROI. 
4.2.3. Immunoprecipitation/Western blot. 
Fresh spinal cord tissue was dissected in ice-cold phosphate buffered saline (PBS) and 
tissue was homogenized in HEPES/sucrose buffer, sonicated on ice, and centrifuged to 
precipitate cell membranes. Membranes were resuspended in RIPA buffer and incubated at 
4°C with mouse anti-HA affinity matrix beads (Roche). Beads were incubated at 55°C 
for 10 minutes in Laemli buffer, run on an SDS-PAGE gel, and transferred onto a 
nitrocellulose membrane. The blots were blocked in 5% milk–TBS/0.1% Tween 20 (TBST) 
for 2 h at room temperature and probed overnight at 4°C with 1:1000 mouse anti-HA 
antibody (Roche) in 1% milk/TBST. Membranes were washed in TBST, probed with 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1:10,000), and processed for 
enhanced chemiluminescence (ECL). 
4.2.4. Immunofluorescence 
Mice were anesthetized with avertin and then perfused with ice-cold 4% 
paraformaldehyde. Spinal cords were removed, post-fixed in 4% paraformaldehyde, and 
cryoprotected in 30% sucrose overnight before freezing in Optimum Cutting Temperature 
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Medium (Tissue-Tek; Sakura, Torrance, CA). Frozen tissue was sectioned at 14 µm 
thickness and fixed to slides. Sections were further incubated with primary antibody [1:250 
rabbit anti-HA (Invitrogen); 1:500 mouse anti-NeuN (Millipore); 1:500 mouse anti-GFP 
(Sigma)]. Slices were washed in PBS and the fluorescent secondary antibodies Alexa 594 
conjugated goat anti-mouse, Alexa 594 conjugated goat anti-rabbit, Alexa 488 conjugated 
goat anti-mouse, and Alexa 488 conjugated goat anti-rabbit were used. Slides were washed, 
dried, and cover slipped. Colocalization of HA and GFP or NeuN was visualized with a 
confocal microscope. For GFAP-tdTomato characterization, colocalization of tdTomato with 
GFP, NeuN, and HA was visualized with a confocal microscope. 
4.3. RESULTS 
4.3.1. Gq-DREADD is expressed in spinal cord astrocytes, but not neurons. 
Gq-DREADD was derived from the Gq-coupled M3 muscarinic receptor (Armbruster et 
al., 2007), which, upon stimulation, activates Gq-GPCR driven signal cascades, including 
IP3-dependent calcium increases. We prepared a transgenic mouse line that expresses Gq-
DREADD under the control of the GFAP promoter (Brenner et al., 1994). Gq-DREADD 
contains a human influenza hemagglutinin (HA) epitope tag to facilitate immunolabeling. In 
the spinal cord, Gq-DREADD was expressed throughout the grey matter of the dorsal and 
ventral horns (Figure 8A). Gq-DREADD-expressing cells in the spinal cord showed the 
classic “bushy” morphology of astrocytes. Spinal cord expression was confirmed by western 
blot analyses that showed Gq-DREADD expression in spinal cord tissue from Gq-DREADD 
but not WT mice (Figure 8B). Immunohistological studies indicated that Gq-DREADD is 
restricted to astrocytes in the brain, satellite glia in the DRG, and non-myelinating Schwann 
cells in the peripheral nervous system (data not shown.) 
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GFAP-GFP mice have been extensively used to identify astrocytes (Zhuo et al., 1997). 
GFAP-GFP mice were crossed with Gq-DREADD mice to quantify the percentage of 
astrocytes expressing Gq-DREADD in the spinal cord. In the dorsal horn of Gq-DREADD × 
GFAP-GFP mice, 55% (20/36) of GFAP-GFP-positive cells expressed Gq-DREADD (Figure 
8C-E). There were some Gq-DREADD-positive cells that did not express GFAP-GFP.  
However, these cells all had typical astrocyte morphology. The neuronal nuclei marker, 
NeuN, was used to label neurons; 0% (0/277) of NeuN-positive cells in the spinal cord 
expressed Gq-DREADD (Figure 8F-H). These results indicate that Gq-DREADD expression 
is restricted to GFAP-positive glia, and that any phenotype seen upon Gq-DREADD 
stimulation can be attributed to activating glial Gq-GPCR signaling cascades. 
To confirm that Gq-DREADD is restricted to astrocytes, we made the GFAP-tdTomato 
transgenic mouse and crossed it to the Gq-DREADD mouse. Cells expressing GFAP-
tdTomato had typical astrocyte morphology (Figure 9A, D, and G). GFAP-tdTomato (Figure 
9A) and the astrocyte marker, GFAP (Figure 9B) were highly colocalized in the dorsal horn 
of spinal cord (Figure 9C). By contrast, GFAP-tdTomato (Figure 9D) and the neuronal 
marker, NeuN, (Figure 9E) did not colocalize in the dorsal spinal cord (Figure 9F). These 
findings suggest that GFAP-tdTomato+ cells are astrocytes. When GFAP-tdTomato mice 
were crossed with Gq-DREADD mice, the vast majority (91%; 21/23) of spinal cord GFAP-
tdTomato+ cells co-expressed Gq-DREADD. (Figure 9G-I). 
4.3.2. Gq-DREADD stimulation causes calcium increases in Gq-DREADD, but not WT 
spinal cord astrocytes. 
In the spinal cord, both lamina II and V are involved in nociceptive information 
processing (Light and Perl, 1979a; Besson et al., 1972). Calcium-imaging studies were 
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performed to determine whether glial Gq-DREADD stimulation induces calcium increases in 
lamina II and V astrocytes (Figure 10). Gq-DREADD mice were bred to GFAP-tdTomato 
mice to use tdTomato to identify spinal cord astrocytes. Acute spinal cord slices were 
prepared and loaded with the calcium indicator dye fluo-4. In Gq-DREADD × GFAP-
tdTomato slices, application of 10 µM CNO caused calcium increases in lamina II astrocytes 
(13/27; n = 2 mice, Figure 10A) and lamina V astrocytes (10/20; n = 2 mice, Figure 10B). In 
GFAP-tdTomato slices, application of 10 µM CNO failed to increase calcium in lamina II 
astrocytes (0/18; n= 2 mice, Figure 10C) or lamina V astrocytes (0/8; n = 2 mice, Figure 
10D). As a positive control, we measured calcium increases in response to an agonist cocktail 
(10 µM each: (S)-3,5-Dihydroxyphenylglycine (DHPG), histamine, and carbachol). The 
majority of astrocytes in both Gq-DREADD × GFAP-tdTomato (19/27 in lamina II; 11/20 in 
lamina V) and GFAP-tdTomato (11/18 in lamina II; 5/8 in lamina V) slices responded to the 
agonist cocktail (Figure 10A-D). Quantification of astrocytes responding is summarized in 
Table 1. Overall, our findings demonstrate that Gq-DREADD is localized to astrocytes in 
laminae II and V and activates Gq-GPCR signaling cascades. 
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Table 1. Quantification of GFAP-tdTomato-positive astrocytes responding to 
CNO and cocktail in spinal cord slices from Gq-DREADD × GFAP-tdTomato 
mice. 
Genotype/lamina % cells responding to 
CNO 
% cells responding 
to agonist cocktail 
Gq-DREADD × GFAP-
tdTomato Lamina II 
13/27 (48%) 19/27 (70%) 
Gq-DREADD × GFAP-
tdTomato Lamina V 
10/20 (50%) 11/20 (55%) 
GFAP-tdTomato Lamina II 0/18 (0%) 11/18 (61%) 
GFAP-tdTomato Lamina V 0/8 (0%) 5/8 (63%) 
 
Many lamina II and V astrocytes in both GFAP-tdTomato and Gq-DREADD × GFAP-
tdTomato slices responded to the positive control agonist cocktail with calcium increases. 
Astrocytes in lamina II and V from Gq-DREADD × GFAP-tdTomato slices responded to 
CNO while astrocytes in both lamina II and V from GFAP-tdTomato slices failed to respond 
to CNO with calcium increases. 
4.4. DISCUSSION 
Both immunohistochemistry and Western blot data demonstrated that Gq-DREADD is 
selectively expressed in glia. Stimulation of glial Gq-DREADD with CNO elicited calcium 
increases in lamina II and V spinal cord astrocytes. This finding suggests that Gq-DREADD 
signaling recapitulates that of endogenous glial Gq-GPCRs and further validates our 
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experimental model. Future studies will examine calcium signaling in peripheral GFAP+ glia 
to bolster our observations by immunohistochemistry for Gq-DREADD expression in DRG 
and peripheral nerves. 
All of our data suggests that Gq-DREADD is expressed in GFAP+ glia. We however 
cannot exclude the possibility that Gq-DREADD is expressed in a small population of 
neurons not examined in our studies. Furthermore, we are assuming that Gq-DREADD 
signaling is comparable to that of endogenous GPCRs. Stimulation of Gq-DREADD 
expressed in cell lines activates MAPK signaling through interactions with β-arrestin 
similarly to activated native GPCRs (Armbruster et al., 2007; Armbruster and Roth, 2005). In 
our mouse model, Gq-DREADD may be expressed at significantly higher levels than 
endogenous Gq-GPCRs, and therefore the possibility exists that signaling might be altered. 
Now that the Gq-DREADD mouse model has been validated, we can investigate how glial 
Gq-GPCRs modulate pain and itch processing. 
CHAPTER 5.  
STIMULATION OF GLIAL GQ-DREADD BLOCKS ACUTE PAIN. 
5.1. INTRODUCTION 
Excitatory and inhibitory synaptic drive must be exquisitely balanced to maintain CNS 
homeostasis. In chronic pain, dysregulation of synaptic drive occurs at multiple sites in the 
nervous system, including the dorsal horn of the spinal cord (Andrew and Craig, 2001; 
Basbaum, 1999). The causes of this dysregulation remain elusive, and a better understanding 
of the mechanisms of neuropathic pain may lead to novel treatments. 
Changes in intracellular signaling systems lead to sensitization of the cells within the 
dorsal horn. While neurons have historically been the focus of studies on neuropathic pain, it 
is now clear that glia play an important role in the establishment and maintenance of chronic 
pain states (Scholz and Woolf, 2007). Glial fibrillary acidic protein positive (GFAP-positive) 
glia release a variety of molecules including inflammatory cytokines that lead to the chronic 
sensitization of nociceptive neurons (Milligan and Watkins, 2009). Astrocytes— a type of 
GFAP-positive glial cell— envelope tens of thousands of synapses (Oberheim et al., 2009). 
Astrocytes also regulate synaptic activity through the release of neuroactive molecules 
(Schell et al., 1995; Zhang et al., 2003; Eroglu and Barres, 2010; Bezzi et al., 2001; Bowser 
and Khakh, 2004) and by buffering potassium (D'Ambrosio et al., 1999) and glutamate 
(Huang et al., 2004). Thus, GFAP-positive glia are well-positioned to modulate synaptic 
activity related to pain processing. 
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The role that GFAP-positive glial Gq-GPCRs play in nociception is unknown. As 
neurons and GFAP-positive glia express many of the same GPCRs, it is difficult to 
selectively stimulate signaling pathways in GFAP-positive glia to evaluate the role of these 
pathways in physiology and pathology. Recently, a novel Gq-GPCR (Gq-DREADD or 
Designer Receptor Exclusively Activated by Designer Drug) was engineered to respond only 
to the pharmacologically inert ligand CNO (Armbruster et al., 2007). To determine how 
selective stimulation of glial Gq-GPCR signaling cascades affects nociception, we utilized a 
transgenic mouse line that expresses Gq-DREADD under the control of the GFAP promoter. 
Our data strongly suggest that the Gq-DREADD mouse model allows selective 
stimulation of Gq-GPCR signaling pathways in GFAP-positive glia. Thus, the Gq-DREADD 
mouse is a powerful new tool for studying the role of glial signaling pathways in pain 
transmission neurocircuitry. The Hargreaves test was used to measure the effect of glial Gq-
GPCR signaling on acute thermal nociceptive processing. Our findings suggest that GFAP-
positive glial Gq-GPCR signaling pathways mediate antinociception in response to acute 
noxious thermal stimuli. 
5.2. MATERIALS AND METHODS  
5.2.1. Transgenic mice. 
Gq-DREADD mice were bred to IP3R2 KO mice (Li et al., 2005), and FosGFP mice 
(Barth et al., 2004). 
5.2.2. Hargreaves test. 
Each mouse was placed in a small clear container on an elevated glass plate. After 60 
minutes of habituation, when the mice were inactive, but not asleep, a low intensity thermal 
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beam was applied to the footpad of each hind paw. The latency for each mouse to respond to 
this beam with a definite paw flick response was recorded. The beam was cut off after a 
maximum of 20s to prevent tissue damage. CNO was injected either intrathecally or 
intraperitoneally. For intrathecal injections, unanesthetized mice were injected using the 
direct lumbar puncture method (Fairbanks, 2003). 
5.2.3. Von Frey test. 
Each mouse was placed in a small clear container on an elevated mesh floor. Calibrated 
Von Frey hairs were applied to the plantar surface of the hind paws and the frequency to 
respond to noxious and innocuous stimuli as well as the paw withdrawal threshold were 
measured. For the frequency measurements, Von Frey hairs were applied ten times and the 
number of paw withdrawal responses was counted. The “up down” method was used to 
measure paw withdrawal threshold, ie. the force in grams at which the mouse withdrew its 
paw fifty percent of the time (Chaplan et al., 1994). 
5.2.4. C-fos Induction. 
For formalin induction, mice were injected in one plantar hind paw with 10 µL of 2% 
formalin. Two hours after formalin injection, anesthetized mice were perfused with 4% 
paraformaldehyde. Spinal cords were removed, post fixed, and cryoprotected in 20% 
sucrose/PBS before freezing. Frozen tissue was sectioned and fixed to slides. For 
visualization of c-fos-positive nuclei in FosGFP sections, sections were incubated with 1:500 
mouse anti-GFP (Sigma), washed in PBS, and incubated with the fluorescent secondary 
antibody Alexa 594 conjugated goat anti-mouse. Quantification of c-fos positive nuclei was 
performed with ImageJ software with the cell counter plug-in. 
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5.2.5. Dorsal root stimulation. 
Acute transverse (800-900 µm) spinal cord slices with one dorsal root were prepared 
(Wang and Zylka, 2009). The lumbar spinal cord was quickly removed from anesthetized 
mice and sectioned on a vibratome in oxygenated ice-cold slicing buffer. The slices were 
incubated in oxygenated ACSF at 37°C for 1 hour and then maintained at room temperature 
in oxygenated ACSF. For recordings, slices were placed in a chamber that was continuously 
perfused with room temperature, oxygenated ACSF. A suction-stimulating electrode was 
used to stimulate peripheral nociceptors in the dorsal root. A recording electrode was pulled 
from borosilicate glass to a resistance of 1-2 MΩ, filled with ACSF, and placed in lamina II 
to record evoked field excitatory post synaptic potentials. The amplitude of field potentials 
elicited by a 200 µs pulse was monitored and the strength of the stimulation was adjusted to 
achieve a half-maximal response. The root was stimulated at 0.1 Hz and every six signals 
were averaged to give a single point per minute of recording. Data analysis was performed 
using pClamp 10 software. The field potential waveform consisted of an early, narrow peak 
mediated by A-delta fibers and a later, broader peak mediated by C-fibers and polysynaptic 
activity. For each Gq-DREADD spinal cord slice, baseline data was recorded for five 
minutes, after which data were recorded for five minutes as 10 µM CNO was bath-applied 
and for the following twenty-minute wash period. 
5.3. RESULTS 
5.3.1. Gq-DREADD mice do not have a basal difference in mechanical sensitivity 
compared to WT littermates. 
To determine whether Gq-DREADD mice have a basal difference in sensitivity to 
mechanical stimuli compared to WT littermates, we measured mechanical sensitivity to 
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punctate stimuli using calibrated Von Frey filaments (Chaplan et al., 1994). We found no 
difference in sensitivity to either a low-intensity, innocuous (0.4 g) mechanical stimulus 
(Frequency of paw withdrawal, WT = 2.3 ± 0.3, Gq-DREADD = 2.0 ± 0.2, WT n = 12, Gq-
DREADD n = 24, student’s T test p = 0.26, Figure 11A) or a high intensity, noxious (1.4 g) 
mechanical stimulus (Frequency of paw withdrawal, WT = 7.6 ± 0.4, Gq-DREADD = 7.4 ± 
0.3, WT n = 12, Gq-DREADD n = 24, student’s T test p = 0.63, Figure 11B) between Gq-
DREADD mice and WT littermates. Finally, we measured paw withdrawal threshold and 
found no difference between Gq-DREADD mice and WT littermates (Paw withdrawal 
threshold, WT = 1.1 ± 0.1 g, Gq-DREADD = 1.2 ± 0.1 g, WT n = 12, Gq-DREADD n = 24, 
student’s T-test, p = 0.48, Figure 11C). 
5.3.2. Stimulation of spinal and/or dorsal root ganglia (DRG) glial Gq-DREADD causes 
an increase in withdrawal latency in an acute thermal nociceptive assay. 
We next examined the effect of stimulating Gq-GPCR pathways in GFAP-positive glia 
on acute noxious thermal sensitivity using the Hargreaves method (Hargreaves et al., 1988). 
No differences in paw withdrawal latencies were seen in Gq-DREADD or WT mice prior to 
injection of CNO (Paw withdrawal latency at 0 minutes, WT = 10.8 ± 1.5 s, Gq-DREADD = 
9.9 ± 1.6 s, Figure 12A). Injection of CNO (1 mg/kg intraperitoneally (I.P.)) caused large 
increases in paw withdrawal latency in Gq-DREADD but not WT mice. The effect occurred 
within 15 minutes of the injection and lasted for the 4-hour measurement period. (Paw 
withdrawal at 60 minutes, WT = 9.1 ± 1.6 s, Gq-DREADD = 16.0 ± 1.8 s; WT n = 9, Gq-
DREADD n = 10, 2-way Repeated Measures ANOVA: genotype, p < 0.001, time course × 
genotype, p = 0.01). When Gq-DREADD and WT mice received 0.5 mg/kg CNO I.P., the 
same rapid and dramatic increase in paw withdrawal latency appeared in Gq-DREADD but 
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not WT mice (Paw withdrawal at 30 minutes, WT = 9.9 ± 1.5 s, Gq-DREADD = 16.9 ± 1.7 s; 
WT n = 9, Gq-DREADD n = 10, 2-way Repeated Measures ANOVA: genotype, p < 0.01, 
Figure 12B). However, the effect subsided after 2.5 hours. These data indicate that 
stimulation of Gq-GPCR pathways in GFAP-positive glia is antinociceptive in an acute 
model of thermal pain. 
Nociceptive processing occurs in the peripheral nervous system, spinal cord, and 
supraspinal regions (Burgess and Perl, 1967; Harris, 1921; Brooks and Tracey, 2005; Urban 
and Gebhart, 1999). Gq-DREADD is expressed in GFAP-positive glia in the spinal cord as 
well as in supraspinal regions, DRG, and peripheral nerves (unpublished observations). To 
determine whether supraspinal regions were required for the antinociceptive thermal 
phenotype seen upon systemic glial Gq-DREADD stimulation, we performed the Hargreaves 
test following intrathecal (I.T.) injections of CNO or saline. I.T. injections are used to deliver 
drugs to both the spinal cord (Hylden and Wilcox, 1980) and DRG (Michael et al., 1997) 
while excluding supraspinal regions. No significant differences in paw withdrawal latencies 
were seen in Gq-DREADD or WT mice prior to I.T. injection of CNO or saline (Paw 
withdrawal latency at 0 minutes, WT/saline = 10.1 ± 1.3 s, Gq-DREADD/saline = 9.4 ± 0.9 s, 
WT/CNO = 11.7 ± 1.0 s, Gq-DREADD/CNO = 11.2 ± 1.1 s, Figure 12C). I.T. injection of 
saline did not affect paw withdrawal latency for either Gq-DREADD or WT mice (Paw 
withdrawal latency at 60 minutes, WT/saline = 8.0 ± 1.3 s, Gq-DREADD/saline = 9.0 ± 0.9 s, 
WT/saline n = 10, Gq-DREADD/saline n = 18). Injection of CNO (30 nmol, I.T.) caused a 
marked increase in paw withdrawal latency in Gq-DREADD but not WT mice, an effect that 
lasted for 4 hours (Paw withdrawal latency at 60 minutes, WT/CNO = 9.3 ± 1.6 s, Gq-
DREADD/CNO = 15.9 ± 1.2 s, WT/CNO n = 10, Gq-DREADD/CNO n = 17, 2-way 
 53 
Repeated Measures ANOVA: genotype, p <0.01, time course × genotype, p < 0.001). A 
lower dose of CNO (1 nmol, I.T.) did not affect paw withdrawal latency for either Gq-
DREADD or WT mice (Paw withdrawal latency at 60 minutes, WT = 11.2 ± 0.6 s, Gq-
DREADD = 11.3 ± 0.7 s, WT n = 8, Gq-DREADD n = 10, 2-way Repeated Measures 
ANOVA: genotype, p = 0.62, Figure 12D). Thus, the ability of intrathecal CNO to decrease 
thermal sensitivity for Gq-DREADD mice is dose-dependent. Our findings support an 
antinociceptive role for Gq-GPCR pathways in GFAP-positive glia in the spinal cord and/or 
DRG in regards to acute thermal sensitivity. 
5.3.3. Stimulation of glial Gq-DREADD causes antinociception in an IP3R2-independent 
manner. 
Calcium increases are a major mode of excitability for astrocytes (Cornell-Bell et al., 
1990b). Astrocyte calcium increases are linked to several physiological phenomena ranging 
from gliotransmission— the release of neuroactive molecules such as glutamate, adenosine 
triphosphate (ATP), and D-serine from glia— (Parpura et al., 1994) and modulation of 
cerebrovascular dynamics (Straub and Nelson, 2007) to pathophysiological states such as 
epilepsy (Kang et al., 2005). Stimulation of Gq-GPCRs triggers phospholipase C (PLC) 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to IP3 and diacylglycerol (DAG) 
(Michell, 1975). IP3 binds IP3 receptors on the endoplasmic reticulum (ER) and induces 
calcium release (Streb et al., 1983). IP3R2 is necessary for astrocytic, but not neuronal, 
calcium increases in the hippocampus (Petravicz et al., 2008). 
To test whether IP3R2 mediates astrocytic calcium increases in the spinal cord dorsal 
horn, we performed calcium-imaging experiments in spinal cord slices from IP3R2 knockout 
(KO) mice. Cells in WT and KO spinal cord slices were loaded with the calcium indicator 
 54 
dye fluo-4 (Figure 13A). While an agonist cocktail elicited calcium increases from the 
majority of cells (91.9%; 34/37 cells) in lamina II in WT slices, none of the cells in lamina II 
in slices from IP3R2 KO mice responded (0%; 0/27 cells; Figure 13B-C.) These results 
support our hypothesis that calcium increases in the spinal cord dorsal horn depend on the 
presence of IP3R2. 
Gliotransmission modulates baseline mechanical nociception (Foley et al., 2011). To 
test whether the Gq-DREADD-mediated antinociception to an acute noxious thermal stimulus 
depended on the ability of astrocytes to produce calcium increases from the ER, we bred Gq-
DREADD mice to IP3R2 KO mice. In the Hargreaves test, none of the mice exhibited 
significant differences in basal thermal sensitivity (Paw withdrawal latency at 0 minutes, 
WT/saline = 9.7 ± 1.3 s, WT/CNO = 9.8 ± 1.4 s, Gq-DREADD/saline = 9.0 ± 1.3 s, Gq-
DREADD/CNO = 8.0 ± 1.4 s, IP3R2 KO/saline = 10.1 ± 1.4 s, IP3R2 KO/CNO = 9.6 ± 2.1 s, 
Gq-DREADD × IP3R2 KO/saline = 7.4 ± 1.0 s, Gq-DREADD × IP3R2 KO/CNO = 11.1 ± 1.7 
s, WT/saline n = 12, WT/CNO n = 12, Gq-DREADD/saline n = 8, Gq-DREADD/CNO n = 8, 
IP3R2 KO/saline n = 5, IP3R2 KO/CNO n = 5, Gq-DREADD × IP3R2 KO/saline n = 5, Gq-
DREADD × IP3R2 KO/CNO n = 5, Figure 13D-E). Mice then received intrathecal injections 
of either saline or 30 nmol CNO. Saline did not affect the withdrawal latency of Gq-
DREADD, WT, IP3R2 KO, or Gq-DREADD × IP3R2 KO mice (Paw withdrawal latency at 
60 minutes, WT/saline = 8.1 ± 1.3 s, Gq-DREADD/saline = 8.5 ± 1.8 s, IP3R2 KO/saline = 
10.7 ± 1.5 s, Gq-DREADD × IP3R2 KO/saline = 6.3 ± 1.4 s). CNO had no discernable effect 
on WT or IP3R2 KO mice but caused a long lasting increase in paw withdrawal latency for 
both Gq-DREADD and Gq-DREADD × IP3R2 KO mice (Paw withdrawal latency at 60 
minutes, WT/CNO = 9.5 ± 1.4 s, Gq-DREADD/CNO = 17.4 ± 1.4 s, IP3R2 KO/CNO = 8.3 ± 
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1.4 s, Gq-DREADD × IP3R2 KO/CNO = 18.0 ± 1.8 s, 2-way Repeated Measures ANOVA: 
genotype, p < 0.05). The antinociceptive effect of Gq-DREADD stimulation on thermal 
sensitivity appears to be independent of the ability of Gq-GPCRs on astrocytes to generate 
calcium increases from the ER. 
5.3.4. Gq-DREADD stimulation decreases the response to an acute noxious heat 
stimulus. 
A variety of noxious stimuli have been shown to induce c-fos in the dorsal horn of the 
spinal cord (Hunt et al., 1987). To test the hypothesis that c-fos is a marker for changes in 
dorsal horn neuronal activity mediated by Gq-DREADD activation, we performed 
intraplantar injection of the hind paw with formalin to induce c-fos in the dorsal horn (Figure 
14). Intraplantar formalin is well validated in generating acute inflammatory pain (Tjolsen et 
al., 1992). FosGFP transgenic mice (Barth et al., 2004) were bred with Gq-DREADD mice to 
allow fluorescent labeling of c-fos positive cells. 
Intraplantar formalin injection induced c-fos in the ipsilateral— but not contralateral— 
superficial dorsal horn for both Gq-DREADD × FosGFP mice pretreated with saline (n=2) or 
CNO (n=2) and control FosGFP mice pretreated with saline (n=1). Regardless of genotype or 
drug, significantly more c-fos was induced in the ipsilateral dorsal horn than in the 
contralateral dorsal horn (Fold change in c-fos positive nuclei in ipsilateral vs. contralateral 
dorsal horn, control FosGFP/saline = 3.3 ± 0.5, Gq-DREADD × FosGFP /saline = 3.2 ± 0.4, 
Gq-DREADD × FosGFP/CNO = 2.9 ± 0.6). These data suggest that while noxious stimuli 
induce c-fos in the dorsal horn, c-fos is not a useful marker for neuronal changes elicited by 
stimulation of Gq-GPCR pathways in GFAP-positive glia. 
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5.3.5. DREADD stimulation does not affect excitatory synaptic drive from the 
periphery to lamina II. 
Primary afferents have their central projections in laminae I and II of the dorsal horn of 
the spinal cord (Light and Perl, 1979a; Light and Perl, 1979b). In acutely isolated spinal cord 
slices, the dorsal root can be stimulated to generate evoked field potentials in lamina II 
(Figure 15A) (Street et al., 2011). To test whether the antinociceptive phenotype seen upon 
DREADD stimulation was due to modulation of excitatory drive from peripheral nociceptors, 
we measured the effect of DREADD stimulation on evoked excitatory field potentials in 
lamina II (Figure 15B). Applying CNO to DREADD spinal cord slices did not affect either 
the magnitude or kinetics of evoked field potentials in lamina II. Therefore, stimulation of 
Gq-GPCR pathways in GFAP+ glia does not appear to modulate excitatory drive from 
peripheral nociceptors. 
5.4. DISCUSSION 
In this study, we examined glial signaling in acute pain using the novel GFAP Gq-
DREADD mouse model. Gq-DREADD and WT mice do not differ in basal mechanical 
sensitivity. Stimulation of glial Gq-DREADD caused antinociception in response to an acute 
noxious heat stimulus. This antinociceptive phenotype involves spinal and/or DRG glial Gq-
DREADD. Astrocyte calcium increases via IP3 receptors have been implicated in astrocyte 
modulation of neuronal activity (Sheppard et al., 1997; Weerth et al., 2007). Removal of 
IP3R2 obliterated Gq-GPCR-mediated calcium increases in acute spinal cord slices. However, 
CNO-injection of Gq-DREADD × IP3R2 KO mice caused antinociception of a similar 
magnitude as Gq-DREADD mice in response to acute noxious heat. Stimulation of glial Gq-
DREADD modulates nociceptive neurocircuitry resulting in our observed phenotype. 
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C-fos has been used as a marker of dorsal horn neural activity in response to 
nociceptive stimuli. Intraplantar injection of formalin induced c-fos in the ipsilateral dorsal 
horn; c-fos expression was unaffected by stimulation of Gq-DREADD. Primary afferents 
release glutamate at synapses in lamina II of the dorsal horn; this can be detected as field 
potentials mediated by AMPA receptors (Street et al., 2011). Gq-DREADD stimulation did 
not modulate excitatory neurotransmission at nociceptor-lamina II synapses. 
The observation that stimulation of glial Gq-GPCR pathways is antinociceptive 
surprised us, as most researchers have described a pro-nociceptive role for glia (Guo et al., 
2007; Watkins and Maier, 2005). However, these studies have focused on chronic pain rather 
than the acute pain paradigm that we studied. Furthermore, chronic pain models often cause 
astrogliosis (Sweitzer et al., 2001). Reactive astrocytes, unlike quiescent astrocytes, release 
inflammatory cytokines (Milligan et al., 2003; Raghavendra et al., 2004; Guo et al., 2007; 
Ledeboer et al., 2005) and experience impaired potassium and glutamate buffering 
(D'Ambrosio et al., 1999; Rao et al., 1998; Fine et al., 1996); these changes all lead to 
increased pain sensitivity. Our study provides insight into the role of glial signaling in acute 
pain. 
What could GFAP-positive glia do that would result in an antinociceptive phenotype? 
Stimulation of astrocyte Gq-GPCR pathways has been linked to a number of processes that 
modulate neuronal activity; these include gliotransmission, potassium and glutamate 
buffering, and synapse formation. Blocking Gq-GPCR-mediated, calcium-dependent, 
vesicular release from glia caused an increase in basal mechanical sensitivity (Foley et al., 
2011). This finding — that gliotransmission and pain sensitivity are inversely related— 
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corresponds to our observation that stimulating glial Gq-GPCR pathways, which would 
presumably enhance gliotransmission, is antinociceptive. 
ATP— which has been proposed as a gliotransmitter— is converted to adenosine in the 
extracellular space. Activation of the adenosine A1 receptor has been shown to be 
antinociceptive in both humans (Eisenach et al., 2003; Karlsten and Gordh, 1995) and 
rodents (Gomes et al., 1999; Sawynok et al., 1986). In addition, astrocyte Gq-GPCR signaling 
has been shown to cause potassium uptake into astrocytes (Wang et al., 2012), which could 
decrease neuronal excitability and thus block pain transmission. 
Glia modulate pain by releasing neuroactive substances (Guo et al., 2007; Scholz and 
Woolf, 2007; Ohtori et al., 2004), yet the location in the pain processing neurocircuitry where 
glia exert their effects is unknown. The fact that intrathecal CNO causes antinociception in 
Gq-DREADD mice suggests that spinal cord astrocytes and/or satellite glia in DRG are 
responsible for the reduction in sensitivity to noxious heat. While most of the glial biology 
literature has focused on the role of spinal cord astrocytes in modulation of pain 
transmission, it is clear that satellite glial cells may also play a role in pathogenesis of pain 
(Vit et al., 2008; Jasmin et al., 2010). Additional study will be needed to determine whether 
Gq-GPCR signaling in astrocytes, satellite glial cells, or both regulate acute noxious thermal 
sensitivity. 
IP3R2-dependent astrocyte calcium increases are implicated in modulating neuronal 
excitability, synaptic plasticity, and cerebrovascular tone (Scemes and Giaume, 2006). 
Indeed, removal of IP3R2 abolishes astrocyte calcium increases in the brain (Takata et al., 
2011; Petravicz et al., 2008) and spinal cord. Yet, stimulation of Gq-GPCR pathways on 
GFAP-positive glia decreases thermal pain sensitivity in an IP3R2-independent manner. 
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Gq-GPCR calcium-independent effectors such as Gβγ or DAG may prove to be 
responsible for the decrease in thermal pain sensitivity upon glial Gq-DREADD stimulation. 
Activation of p63RhoGEF-dependent pathways is another calcium-independent Gq-GPCR 
signaling pathway (Rojas et al., 2007).  
 Alternatively, there may be other sources for astrocyte calcium besides release from 
intracellular stores. For example, TRPA1 channels function as a transmembrane calcium 
source for astrocytes and may be sufficient to maintain calcium-dependent signaling 
(Shigetomi et al., 2011). Clearly, the role of calcium in glial biology has yet to be fully 
resolved. 
While Gq-DREADD does not appear to modulate excitatory synaptic transmission from 
the periphery to lamina II, this does not exclude the possibility that our phenotype is being 
mediated by modulation of inhibitory synaptic transmission or by modulation of wide 
dynamic range neurons in lamina V. A loss of inhibitory synaptic tone in the dorsal horn has 
been shown to contribute to neuropathic pain (Moore et al., 2002; Ibuki et al., 1997). 
Astrocyte calcium signaling has been shown to potentiate inhibitory synaptic transmission in 
the hippocampus (Kang et al., 1998). If glial GPCR signaling increased inhibitory drive in 
the spinal cord, this would be antinociceptive. Future studies will examine how glial GPCR 
signaling changes synaptic transmission. 
In conclusion, our data demonstrate that GFAP-positive glial Gq-GPCR pathways are 
antinociceptive for acute noxious thermal stimuli. This is the first study to demonstrate that 
GFAP-positive glial Gq-GPCR pathways play a role in pain. Further study will be needed to 
uncover the mechanism by which glial Gq-GPCRs cause antinociception. 
CHAPTER 6.  
STIMULATION OF GLIAL GQ-DREADD BLOCKS ACUTE ITCH. 
6.1. INTRODUCTION 
Chronic itch is a significant clinical problem that lacks effective treatments (Oaklander, 
2011). New therapeutics will require understanding of signaling mechanisms involved in 
itch. To this end, we used the histamine-induced itch assay (Wilson et al., 2011) to measure 
the effect of glial Gq-GPCR signaling on acute itch processing. Our findings suggest that 
GFAP-positive glial Gq-GPCR signaling pathways block acute histamine-dependent itch. 
6.2. METHODS 
6.3. ITCH BEHAVIORAL TEST. 
Intradermal histamine was used to generate acute itch in mice (Wilson et al., 2011). 
Mice were habituated to the testing environment for 30 minutes before testing and then 
injected intradermally in the nape of the neck with 500 µg of histamine dissolved in 50 µL 
saline. Finally, the number of scratching bouts over 30 minutes was counted. A scratching 
bout was defined as the mouse using its hind paw to scratch the site of histamine injection. 
6.4. RESULTS 
6.4.1. Glial Gq-DREADD stimulation blocks histamine-induced itch. 
Many pathologies that cause neuropathic pain also cause neuropathic itch (Oaklander, 
2011). As glial Gq-DREADD stimulation is antinociceptive for acute noxious thermal 
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stimuli, we conducted acute itch assays to determine whether glial Gq-DREADD stimulation 
also modulates itch-related behaviors. We injected histamine intradermally into the nape of 
the neck, as this has been demonstrated to induce scratching in rodents (Lee et al., 2011). 
Intradermal histamine robustly caused itch in WT mice pretreated with saline or CNO (0.5 
mg/kg, I.P.) and Gq-DREADD mice pretreated with saline (total number of scratches: 
WT/saline = 98.1 ± 14.1, WT/CNO = 76.2 ± 11.5, Gq-DREADD/saline = 130.7 ± 17.9, 
WT/saline n = 6, WT/CNO n = 6, Gq-DREADD/saline n = 7, Figure 16). Pretreatment of Gq-
DREADD mice with CNO (0.5 mg/kg, I.P.) completely blocked histamine-induced itch (total 
number of scratches: Gq-DREADD/CNO = 0.7 ± 0.7, Gq-DREADD/CNO n = 7, 2-way 
ANOVA: CNO factor, p < 0.001 Figure 16). 
6.4.2. Systemic inhibition of glial Gq-DREADD restores histamine-induced itch. 
To confirm that the antipruritic phenotype is mediated through Gq-DREADD, we used 
scopolamine—a CNS-permeable muscarinic antagonist— to rescue histamine-induced itch in 
CNO-injected Gq-DREADD mice (Figure 18A). Again, CNO injection of Gq-DREADD mice 
blocked histamine-induced itch. While scopolamine treatment alone had no effect at a dose 
of 1 mg/kg, it slightly decreased histamine-dependent itch at a dose of 10 mg/kg. When 
blocking peripheral and central glial Gq-DREADD, 1 mg/kg scopolamine did not rescue 
histamine-induced itch in CNO-injected Gq-DREADD mice (total number of scratches: 
saline/saline = 126.9 ± 20.8, saline/CNO, = 0.5 ± 0.4, 1 mg/kg scopolamine/saline = 125.8 ± 
30.2, 1 mg/kg scopolamine/CNO = 3.3 ± 1.2, saline/saline n = 8, saline/CNO n = 8, 1 mg/kg 
scopolamine/saline n = 4, 1 mg/kg scopolamine/CNO n = 4, 2-way ANOVA: CNO 
treatment, p < 0.0001, Scopolamine treatment, p = 0.63, Figure 17A). However, 10 mg/kg 
scopolamine partially rescued histamine-induced itch in CNO-injected Gq-DREADD mice 
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(total number of scratches: 10 mg/kg scopolamine/saline = 63.7 ± 33.7, 10 mg/kg 
scopolamine/CNO = 31.8 ± 12.3, 10 mg/kg scopolamine/saline n = 3, 10 mg/kg 
scopolamine/CNO n = 6, 2-way ANOVA: interaction between CNO and scopolamine 
treatment p = 0.04, Figure 17A). The fact that 10 mg/kg scopolamine partially rescued 
histamine-induced itch in CNO-injected Gq-DREADD mice confirms that glial Gq-GPCR 
signaling can modulate acute itch. 
To measure the effect of scopolamine itself on histamine-induced itch, we measured 
histamine-induced itch responses in WT mice pretreated with saline or scopolamine. 
Histamine-dependent itch in WT mice was significantly affected by pretreatment with 10 
mg/kg scopolamine but not by a 1 mg/kg dose (total number of scratches: WT/saline = 99.3 ± 
12.0, WT/1 mg/kg scopolamine = 77.9 ± 11.3, WT/10 mg/kg scopolamine = 46.9 ± 11.3, 
WT/saline n = 12, WT/1 mg/kg scopolamine n = 7, WT/10 mg/kg scopolamine n = 8, 1-way 
ANOVA: scopolamine treatment, p = 0.02, Figure 17B). The decrease in histamine-induced 
itch in WT mice at the higher dose of scopolamine compared to saline-injected mice is likely 
due to scopolamine’s effects at endogenous muscarinic receptors. 
6.4.3. Inhibition of peripheral glial Gq-DREADD restores histamine-induced itch. 
We next determined whether the antipruritic phenotype was centrally and/or 
peripherally mediated. Scopolamine methyl bromide (SMB)— a central nervous system 
(CNS) impermeable muscarinic antagonist— also blocks Gq-DREADD. Gq-DREADD mice 
were injected with either saline or SMB (1 or 10 mg/kg, I.P.) prior to CNO/saline and 
histamine injections. As expected, Gq-DREADD mice pretreated with saline or either dose of 
SMB and then injected with saline experienced normal histamine-induced itch (total number 
of scratches: saline/saline = 108.4 ± 20.7, 1 mg/kg SMB/saline = 129.6 ± 15.4, 10 mg/kg 
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SMB/saline = 139.8 ± 21.0, saline/saline n = 5, 1 mg/kg SMB/ saline n = 5, 10 mg/kg SMB/ 
saline n = 5, Figure 18A). As seen previously (Figure 16), Gq-DREADD mice pretreated with 
saline prior to CNO injection did not experience histamine-induced itch (total number of 
scratches: saline/CNO = 11.0 ± 5.8, n = 7, 2-way ANOVA: CNO treatment, p < 0.0001, 
Figure 18A). When blocking peripheral glial Gq-DREADD, 1 mg/kg SMB did not rescue 
histamine-induced itch and 10mg/kg SMB partially restored histamine-induced itch in CNO-
injected Gq-DREADD mice (total number of scratches: 1 mg/kg SMB/CNO = 16.8 ± 8.7, 10 
mg/kg SMB/CNO = 47.0 ± 11.6, 1 mg/kg SMB/CNO n = 6, 1 mg/kg SMB/CNO n = 5, two-
way ANOVA: SMB treatment, p = 0.06). 
To determine whether SMB by itself effects histamine-induced itch, we performed 
acute itch experiments with WT mice and two doses of SMB. WT mice injected with 1 
mg/kg SMB or 10 mg/kg SMB experienced less histamine-induced itch than saline-injected 
mice (total number of scratches: WT/saline = 151.7 ± 10.0, WT/1 mg/kg SMB = 86.0 ± 17.0, 
WT/10 mg/kg SMB = 83.2 ± 11.1, WT/saline n = 6, WT/1 mg/kg SMB n = 6, WT/10mg/kg 
SMB n = 5, 1-way ANOVA with Bonferroni’s post-hoc tests were used to compare each 
drug treatment to saline: p < 0.05, Figure 18B). The decrease in histamine-induced itch in 
SMB-injected mice compared to saline-injected mice is likely due to SMB’s effects at 
endogenous muscarinic receptors. 
The fact that SMB and scopolamine had similar effects on histamine-induced itch in 
CNO-injected Gq-DREADD mice indicates that stimulation of Gq-DREADD in peripheral 
GFAP-positive glia— non-myelinating Schwann cells and/or satellite glial cells— blocks 
acute histamine-dependent itch. The small but significant reduction in histamine-induced itch 
in SMB-treated and scopolamine-treated WT mice may explain why both scopolamine and 
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SMB gave a partial, rather than full, rescue of histamine-induced itch in CNO-injected Gq-
DREADD mice. 
6.5. DISCUSSION 
Almost nothing is currently known about the role of glia in itch perception. Stimulation 
of Gq-GPCR pathways in GFAP-positive glia obliterated acute histamine-dependent itch. 
Pharmacological data suggest that peripheral glial Gq-GPCR signaling pathways are involved 
in blocking histamine-induced itch. Peripheral C-fibers, which have been implicated in the 
transmission of pruritogenic stimuli, are closely associated with non-myelinating Schwann 
cells (Schmelz et al., 1997). Non-myelinating Schwann cells express GFAP (Jessen et al., 
1990) and respond to stimulation of purinergic receptors by releasing calcium from 
intracellular stores (Mayer et al., 1998). Non-myelinating Schwann cells also provide trophic 
support to C-fibers (Chen et al., 2003). Since Gq-DREADD has been detected in both non-
myelinating Schwann cells and in satellite glial cells in Gq-DREADD mice (data not shown), 
it seems likely that Gq-GPCR signaling in peripheral GFAP-positive glia mediates the anti-
itch phenotype. Further study will be needed to determine the mechanism by which glia 
inhibit itch. 
There are no effective therapeutics for chronic itch. Our research focused on the role of 
glial signaling on acute itch. Future study will be needed to determine whether glial Gq-
GPCR signaling pathways modulate chronic itch states. The majority of therapeutically 
useful agents target GPCRs (Pierce et al., 2002). A greater understanding of glial modulation 
of itch neurocircuitry may lead to improved treatments for itch. 
CHAPTER 7.  
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
7.1. CURRENT PROBLEMS IN PAIN AND ITCH RESEARCH 
Researchers have developed few effective treatments for chronic pain and itch over the 
last 50 years, largely because despite a tremendous basic research effort, we still do not 
completely understand the mechanisms of these disorders. This is astounding when we 
consider that chronic pain and itch affect 30.7% and 23% of adults, respectively (Johannes et 
al., 2010; Matterne et al., 2009). 
The vast majority of studies on pain and itch rely on animal models for ethical reasons. 
Unfortunately, animal models of pain face serious limitations that hamper our ability to study 
these phenomena. Mechanical allodynia is hypersensitivity to normally innocuous tactile 
stimuli whereas exaggerated responses to noxious thermal stimuli is the definition of thermal 
hyperalgesia. Since animals cannot speak, it is difficult for pain researchers to assess 
spontaneous pain in animals. Researchers are generally limited to measuring hypersensitivity 
evoked by mechanical or thermal stimuli. However, the primary complaint of pain patients is 
spontaneous pain, not mechanical allodynia or thermal hyperalgesia (Mogil and Crager, 
2004). While the Grimace Scale has been recently developed to measure spontaneous pain in 
rodents, it remains laborious to use and therefore is unlikely to be widely adapted by basic 
pain researchers (Langford et al., 2010; Sotocinal et al., 2011). The basic pain research 
community would benefit greatly from the development of a simple, high-throughput, non-
invasive method for measuring spontaneous pain in animal models. 
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Itch research using animal models faces technical limitations similar to that those 
encountered in pain research. Applying a pruritic stimulus to a human subject elicits two 
kinds of response: a verbal response (i.e. “I feel itchy”) and a site-directed response (ie. 
scratching the site of pruritogen application). Obviously, in animals, researchers can only 
measure site-directed responses. The standard method for measuring acute itch in mice is to 
intradermally inject a pruritogen, such as histamine, into the nape of the neck and measure 
the resulting scratch bouts (Green et al., 2006). Algesic agents such as capsaicin also elicit 
scratching in mice when applied in this manner since no other behavioral response is possible 
at this site (Shimada and LaMotte, 2008). Thus, the nape of the neck cannot be used to 
behaviorally differentiate between chemicals that evoke itch and those that cause pain. 
These technical limitations may be partially bypassed by a “cheek model of itch” 
recently developed for use in mice (Shimada and LaMotte, 2008). When histamine and 
capsaicin are injected into the mouse cheek, they produce two site-directed behaviors: the 
former evokes scratching with the hind limb whereas the latter elicits wiping with the 
forelimb. Future studies of pain and itch using mouse models would be well advised to 
employ behavioral assays that can distinguish between pain and itch. 
7.2. THE GQ-DREADD MOUSE MODEL 
7.2.1. Advantages of the Gq-DREADD mouse model. 
The Gq-DREADD mouse can be used as a model for studying the effects of selectively 
stimulating Gq-GPCR pathways in GFAP+ glia in vivo. A major advantage of the Gq-
DREADD mouse model is that injection of the DREADD agonist, CNO, is easy and 
relatively non-invasive. In vitro studies show that stimulating Gq-DREADD with CNO 
causes calcium increases in spinal cord glia and other regions of the CNS (unpublished 
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observations). While we have yet to examine other components of the Gq-GPCR signaling 
pathway, our calcium imaging data suggests that Gq-DREADD signaling recapitulates 
endogenous GPCR signaling. In addition, the ability to control glial Gq-GPCR signaling 
raises the tantalizing prospect of translational applications for Gq-DREADD. A majority of 
FDA approved drugs are taken orally and act through GPCRs (Rogan and Roth, 2011). 
Perhaps in the future, Gq-DREADD technology will be harnessed to control glial Gq-GPCR 
signaling in humans in order to treat nervous system disorders. For example, if glial Gq-
GPCR signaling is found to block chronic pain as well as acute pain, then chronic pain 
patients might benefit from intrathecal injections of viral vectors that drive Gq-DREADD 
expression in glia. 
7.2.2. Disadvantages of the Gq-DREADD mouse model. 
The greatest disadvantage of the Gq-DREADD mouse model is that systemic injection 
of CNO causes a range of phenotypes—increased heart rate, increased saliva formation, 
sedation—that are unrelated to pain or itch. While intrathecal delivery of CNO appears to 
cause antinociception without these additional phenotypes, this delivery method is only 
useful for measuring pain and itch sensitivity in the hind limbs. Another disadvantage of the 
Gq-DREADD mouse model is its low temporal resolution. Systemic delivery of CNO causes 
Gq-DREADD activation in tens of minutes which is much slower than the activation of 
endogenous GPCRs. Cannulas can be placed in the brain to reduce the time needed to deliver 
CNO to selected brain regions, but this method of drug delivery is neither easy nor non-
invasive. 
While this dissertation focuses on the role of Gq-GPCR signaling, Gi-coupled and Gs-
coupled DREADDs have also been developed. As CNO is the only known agonist for all 
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three DREADD signaling systems, multiple DREADDs cannot be studied in the same cell or 
mouse model. Finally, while CNO is a good ligand in mice— it is highly bioavailable, 
penetrates the BBB, and does not undergo back-metabolism to clozapine, which has activity 
at more than 50 neuronal targets (Rogan and Roth, 2011) — CNO is not appropriate for use 
in humans because of significant back-metabolism to clozapine. Therefore, any therapeutic 
use of DREADD technology in humans will require the development of novel DREADD 
ligands. 
7.3. POSSIBLE SIGNALING MECHANISMS 
The Gq-DREADD receptor was generated by making point mutations in the 3rd and 5th 
transmembrane regions of the endogenous M3 muscarinic receptor (Armbruster et al., 2007). 
Since the M3 muscarinic receptor is a Gq-coupled GPCR, it is likely that Gq-DREADD also 
signals through Gq-coupled GPCR pathways. An activated Gq-coupled GPCR stimulates 
PLC, which metabolizes PIP2 into the second messengers IP3 and DAG. Some of the 
downstream signaling effectors that could be responsible for mediating the antinociceptive 
and antipruritic phenotypes seen in the Gq-DREADD mouse have been discussed in Chapters 
5 and 6 respectively. 
In the Gq-DREADD mouse, Gq-DREADD is presumably localized to the plasma 
membrane of GFAP-positive cells. A recently developed approach allows researchers to 
target DREADD to distinct neuronal subdomains (Dong et al., 2010). Glia also have distinct 
subdomains where GPCR activation could possibly differentially activate signaling cascades. 
For example, astrocytes have fine processes that envelope synapses and contact the 
cerebrovasculature (Halassa et al., 2007; Petzold and Murthy, 2011; Giaume et al., 2010); 
there may be different local signaling machinery and scaffolds at these subdomains. The 
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antinociceptive and antipruritic phenotypes that we observed in the Gq-DREADD mouse may 
depend on activation of Gq-GPCRs in specific glial subdomains. 
Finally, while much of the glial research community has focused on G protein-
dependent aspects of Gq-GPCR signaling, G protein-independent signaling via β-arrestins 
may mediate the effects of certain drugs (Rogan and Roth, 2011). For example, clinically 
effective antipsychotics appear to antagonize GPCR signaling through β-arrestins (Masri et 
al., 2008). It is possible that G protein-independent signaling pathways could play a role in 
the ability of Gq-DREADD stimulation to block acute pain and itch. 
7.4. FUTURE DIRECTIONS 
The Gq-DREADD mouse model represents a unique tool for studying the role of glia in 
pain and itch. In Chapter 4, we used immunohistochemistry and calcium imaging studies to 
demonstrate that the Gq-DREADD mouse is a useful tool for studying Gq-GPCR signaling in 
GFAP-positive glia. While Gq-DREADD expression has been extensively characterized in 
the PNS and CNS by immunohistochemistry, functional characterization of Gq-DREADD by 
calcium imaging has largely been limited to the spinal cord dorsal horn, hippocampus, and 
visual cortex. Furthermore, with the exception of in vivo studies performed in the visual 
cortex, most of these calcium imaging studies have used acutely isolated slices. Future 
studies to examine Gq-DREADD-mediated calcium signaling in peripheral glia would add to 
our understanding of glial GPCR signaling in the PNS. In addition, it would be interesting to 
compare in vivo calcium imaging of the dorsal horn with in vitro acute slice calcium imaging 
data. In acute slice experiments, agonist-mediated receptor desensitization occurs within 
minutes of agonist application; this event terminates calcium increases. However, 
preliminary evidence from in vivo calcium imaging suggests that an I.P. injection of CNO in 
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Gq-DREADD mice causes calcium increases in cortical astrocytes that continue for hours. 
CNO injection in Gq-DREADD mice also causes antinociception in response to noxious heat 
that lasts for hours. Further study will be needed to resolve this seeming disconnect between 
in vivo and in vitro data. 
In Chapter 5, we examined the role of glial GPCR signaling in acute pain. Future pain 
studies should focus on elucidating signaling pathways involved in the antinociceptive 
phenotypes. One potential method is to use pharmacological antagonists to block the 
antinociceptive phenotype seen in the Hargreaves test. Potential candidates for the 
antinociceptive phenotype include adenosine and endorphins. 
While our finding that glial GPCRs modulate acute pain is novel and exciting, 
chronic— rather than acute— pain is clinically relevant. Our lab is proficient in using the 
spared nerve injury (SNI) model of chronic neuropathic pain in mice (Shields et al., 2003). 
This model causes long lasting, robust mechanical allodynia, which can easily be assessed 
using calibrated Von Frey hairs. Gq-DREADD mice do not appear to differ from WT 
littermates in their mechanical sensitivity. Insofar as we have observed antinociception to 
noxious heat, it seems worth investigating whether CNO injection of naïve Gq-DREADD 
mice causes also antinociception to mechanical stimuli. Then the role of glial Gq-GPCR 
signaling in chronic pain could be assessed by performing SNI on Gq-DREADD mice and 
measuring mechanical sensitivity at various time points after post-surgery injection of CNO 
or saline. 
In Chapter 6, we examined the role of glial Gq-GPCR signaling in acute itch. Future 
studies would expand on our understanding of the antipruritic phenotype seen upon 
stimulation of glial Gq-DREADD in the acute histamine-induced itch assay. While our 
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preliminary data suggest that peripheral Gq-DREADD signaling mediates the antipruritic 
phenotype, the molecular mechanism remains unknown. The isolated skin-nerve preparation 
allows thermal, mechanical, and chemical stimuli to be applied to the skin and the evoked 
action potentials of single fibers to be measured (Reeh, 1986). This paradigm could be used 
to test the hypothesis that glial Gq-DREADD stimulation blocks acute histamine-induced itch 
by decreasing the activity of C-fibers. This would require making a skin-nerve preparation 
from Gq-DREADD mice, applying histamine to the skin to evoke C fiber responses, and then 
applying CNO or saline to the skin and recording any changes in C fiber responses. 
7.5. SUMMARY AND CONCLUSIONS 
Chronic pain and itch are highly prevalent and devastating disorders that lack effective 
treatments. The Gq-DREADD mouse model represents a powerful new tool for selectively 
activating glial Gq-GPCR pathways in vivo. The experiments presented herein provide insight 
into the previously unknown role of glial Gq-GPCR pathways in acute pain and itch. The 
current state of research generally supports a role for astrocytes in enhancing chronic pain 
states. Our finding that glial Gq-GPCR pathways can block acute pain and itch provides 
insight into an additional physiological role for glia. Further examination of the role of glial 
GPCRs in sensory disorders may lead to the identification of novel targets for drug 
development.
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APPENDIX A.  
FIGURES 
 
 
Figure 1. The Tripartite System. 
Astrocyte fine processes contact the presynaptic and postsynaptic neurons. Stimulation 
of astrocyte calcium is thought to lead to release of gliotransmitters, glutamate, 
ATP/adenosine, and D-serine. Gliotransmitters act at Alpha-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA), NMDA, metabotropic glutamate (mGluR), and 
A1/A2 adenosine receptors located on either the pre- or post-synaptic neuron. Image 
reprinted from Zorec et al., 2012. 
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Figure 2. The Rat Grimace Scale. 
The four action units of the Rat Grimace Scale are depicted. These correspond to the 
“pain face” that a rat makes when in pain. Image reprinted from Sotocinal et al., 2011. 
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Figure 3. The Itch Man Scale. 
The Itch Man scale was developed to assess itch in pediatric burn patients. Image 
reprinted from Blakeney and Marvin, 2000. 
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Figure 4. The anatomical basis for pain and itch processing. 
The neurocircuitry used to process painful and pruritic stimuli has a large degree of 
overlap. Image reprinted from Ikoma et al,, 2006. 
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Figure 5. Peripheral injury causes astrogliosis in the dorsal horn of the spinal 
cord. 
A variety of injuries including nerve damage, tumor invasion, or tissue damage cause 
astrogliosis in the spinal cord. After spinal nerve ligation (SNL), reactive astrocytes undergo 
hypertrophy and upregulate expression of GFAP. Image reprinted from Gao and Ji, 2010. 
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Figure 6. The MrgA1 transgenic mouse model allows selective activation of 
astrocytic Gq-GPCRs. 
(A) Crossing hGFAP-tTA to tetO-MrgA1 mice resulted in the expression of MrgA1 in 
GFAP+ cells in the absence of doxycycline. (B) MrgA1 is fused to GFP. In the hippocampus, 
astrocytes (GFAP), but not neurons (NeuN), expressed the MrgA1 receptor. (C) NG2+ glia 
did not express the MrgA1 receptor. (D) A higher magnification shows overlapping 
expression of GFP (MrgA1) and GFAP (red) in both the astrocyte soma and major processes. 
Image reprinted from Fiacco et al., 2007 
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Figure 7. DREADDs are mutated muscarinic receptors. 
(A) DREADD (hM3D) is formed by making two point mutation in the 3rd and 5th 
transmembrane regions of the endogenous M3 muscarinic receptor (hM3): stars; Y149C and 
A239G). (B) In human pulmonary artery smooth muscle cells, the wild-type hM3 is potently 
activated by acetylcholine (ACh), but not CNO, resulting in PIP 2 hydrolysis. Conversely, 
hM3D is activated by CNO, but not ACh.  Image reprinted from Rogan and Roth, 2011. 
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Figure 8. Gq-DREADD is expressed in spinal cord astrocytes, but not neurons. 
(A) HA-tagged Gq-DREADD (green) and DAPI (blue) staining of the spinal cord (Scale 
bar = 500 µM). (B) Western blot of spinal cord from Gq-DREADD and WT mice. (C) The 
dorsal horn of the spinal cord from a GFAP-GFP mouse bred to a Gq-DREADD mouse. 
GFP-positive spinal cord astrocytes are shown in green. Scale bar = 100 µm. (D) 
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Immunostaining for HA-tagged Gq-DREADD is shown in red. (E) GFP-positive astrocytes 
showed colocalization (marked with arrows) with the HA-epitope tagged Gq-DREADD. (F) 
HA-tagged Gq-DREADD immunostaining (green). Scale bar = 50 µm. (G) The dorsal horn 
of the spinal cord was immunostained for the neuronal marker, NeuN (red, marked with 
arrows). (H) No colocalization was found between NeuN and Gq-DREADD. 
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Figure 9. GFAP-tdTomato is expressed in spinal cord astrocytes, but not 
neurons. 
(A) GFAP-tdTomato+ cells (arrows) in the spinal cord. (Scale bar = 50 µm). (B) GFAP 
staining of spinal cord (C) Merge of A and B. (D) GFAP-tdTomato+ cell is marked with an 
arrow. (Scale bar = 50 µm) (E) NeuN (F) merge of D and E. (G) GFAP-tdTomato+ cells 
(arrows, Scale bar = 50 µm) (H) HA-Gq-DREADD. (I) Merge of G and H. 
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Figure 10. Gq-DREADD stimulation causes calcium increases in Gq-DREADD 
but not WT spinal cord astrocytes. 
(A) GFAP-tdTomato × Gq-DREADD-positive astrocytes in lamina II respond to CNO 
and a positive control agonist cocktail (10 µm each DHPG, histamine, carbachol). (B) 
GFAP-tdTomato+ × Gq-DREADD lamina V astrocytes respond to CNO and the cocktail with 
calcium increases. (C) GFAP-tdTomato positive astrocytes in lamina II do not respond to 
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CNO but do respond to the cocktail. (D) GFAP-tdTomato astrocytes in lamina V do not 
respond to CNO but do respond to the cocktail. 
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Figure 11. Gq-DREADD and WT littermates have similar basal mechanical 
sensitivity. 
(A) Frequency of paw withdrawal in response to a low-intensity mechanical stimulus. 
(B) Frequency of paw withdrawal in response to a high-intensity mechanical stimulus. (C) 
Paw withdrawal threshold. 
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Figure 12. Stimulation of spinal and DRG glial Gq-DREADD causes an increase 
in withdrawal latency in an acute thermal nociceptive assay. 
(A) CNO (1 mg/kg, I.P.) caused an increase in withdrawal latency for Gq-DREADD 
mice that lasted for almost 4 hours. (B) A lower dose of CNO (0.5 mg/kg, I.P.) caused an 
increase in withdrawal latency for Gq-DREADD mice that lasted for more than 2 hours. (C) 
While there was no difference in baseline paw withdrawal latency, intrathecal injection of 
CNO (30 nmol) caused an increase in paw withdrawal latency in Gq-DREADD but not WT 
mice in the Hargreaves test. Intrathecal injection of saline did not affect withdrawal latency 
for either Gq-DREADD or WT mice. (D) A lower dose of CNO (1 nmol, I.T.) did not cause a 
difference in paw withdrawal latency for Gq-DREADD or WT mice in the Hargreaves test. 
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Figure 13. Stimulation of Gq-GPCR pathways on GFAP-positive glia causes 
antinociception in an IP3R2-independent manner. 
(A) Representative slices in which astrocytes were loaded with fluo-4 calcium indicator 
dye. Regions of interest were placed over cell bodies of bulk-loaded cells in lamina II of the 
dorsal horn to record their responses to agonist application. (B) Representative calcium traces 
to bath application of an agonist cocktail (histamine, carbachol and DHPG; 10 µm each). (C) 
The cocktail elicited robust calcium responses in astrocytes from WT littermate control slices 
(91.9% of 37 cells; n = 3 mice) but not in IP3R2 KO slices (0% of 27 cells; n = 3 mice). (D) 
Gq-DREADD and Gq-DREADD × IP3R2 KO mice experienced a dramatic and long-lasting 
increase in paw withdrawal latency in response to intrathecal injection of 30 nmol CNO, but 
not in response to saline. (E) The paw withdrawal latency for IP3R2 KO and WT mice did 
not change in response to intrathecal injection of either 30 nmol CNO or saline. 
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Figure 14. Gq-DREADD stimulation did not alter induction of c-fos in the dorsal 
horn in response to intraplantar formalin. 
Formalin injected into the plantar surface of the hind paw of a control FosGFP mouse 
induced c-fos in the ipsilateral (A) but not contralateral (B) superficial dorsal horn and was 
not affected by an i.p. saline injection. Formalin injected into the plantar surface of the hind 
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paw of a Gq-DREADD × FosGFP mouse induced c-fos in the ipsilateral but not contralateral 
superficial dorsal horn and was not affected by i.p. saline (ipsilateral – C, contralateral – D) 
or 0.5 mg/kg i.p. CNO (ipsilateral – E, contralateral - F). (G) Quantification of fold 
difference of c-fos induction in the ipsilateral vs. contralateral dorsal horn. (Scale bar = 50 
µm). 
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Figure 15. Gq-DREADD stimulation did not affect excitatory synaptic drive from 
the peripheral primary afferents to lamina II. 
(A) Schematic of experimental set up. A suction electrode stimulated the dorsal root 
while evoked field potentials were recorded in lamina II. (B) Representative traces of evoked 
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field potentials during the baseline, CNO, and wash periods. Data were collected from three 
Gq-DREADD spinal cord slices from two mice. No difference was seen in the evoked field 
potentials recorded during the baseline, CNO application and the wash periods. 
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Figure 16. Glial Gq-DREADD stimulation blocks histamine-dependent itch. 
Pretreatment with saline did not affect histamine-induced itch in WT or Gq-DREADD 
mice. Pretreatment with CNO (0.5 mg/kg I.P.) blocked histamine-induced itch in Gq-
DREADD mice but not WT mice. 
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Figure 17. Systemic inhibition of glial Gq-DREADD restores histamine-induced 
itch. 
(A) Histamine-induced itch in Gq-DREADD mice was not affected by pretreatment 
with saline, 1 mg/kg scopolamine, or 10 mg/kg scopolamine followed by saline injection. Gq-
DREADD mice pretreated with saline or 1 mg/kg scopolamine and then injected with 0.5 
mg/kg CNO did not experience histamine-induced itch. Pretreatment with 10 mg/kg 
scopolamine partially rescued histamine-induced itch in CNO-injected Gq-DREADD mice. 
(B) Histamine-induced itch in WT mice was not affected by injection of 1 mg/kg 
scopolamine compared to saline treatment. Pretreatment of WT mice with 10 mg/kg 
scopolamine caused fewer histamine-induced scratching bouts compared to WT mice 
pretreated with saline * P < 0.05. 
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Figure 18. Inhibition of peripheral glial Gq-DREADD restores histamine-
induced itch. 
(A) Gq-DREADD mice exhibited normal histamine-induced itch when pretreated with 
saline or either dose of SMB followed by a saline injection. Gq-DREADD mice pretreated 
with saline and then injected with CNO did not exhibit histamine-induced itch. Pretreatment 
with 1 mg/kg SMB did not rescue histamine-induced itch in CNO-injected Gq-DREADD 
mice; pretreatment with 10 mg/kg SMB partially rescued histamine-induced itch in CNO-
injected Gq-DREADD mice. (B) Pretreatment of WT mice with 1 mg/kg SMB or 10 mg/kg 
SMB caused fewer histamine-induced scratching bouts compared to WT mice pretreated 
with saline * P < 0.05. 
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